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Mouse embryonic stem (ES) cells are derived from the preimplantation embryo. ES cells 
can be cultured indefinitely in vitro while retaining the capacity to give rise to any cell 
type of an organism. To maintain the self-renewal and pluripotency of ES cells, 
transcription factors play critical roles via the activation of the ES cell specific gene 
expression program. Nanog is a homeodomain-containing protein that has been identified 
to be important both for the early development of the blastocyst and the maintenance of 
undifferentiated ES cells. However, the mechanisms underlying the function of Nanog 
remain unclear. This project aims to identify the downstream effectors responsible for 
implementing the decision of Nanog to maintain the self-renewal state of ES cells. 
Through the manipulation of Nanog level by RNAi knockdown and overexpression, 
putative target genes positively regulated by Nanog were identified. Among the Nanog 
target genes is a gene encoding for nuclear receptor protein Esrrb (Estrogen-related 
receptor, beta). Interestingly, Esrrb is also positively regulated by another key factor of 
ES cells, Oct4. Chromatin immunoprecitation (ChIP) and electrophoretic mobility shift 
assay (EMSA) further demonstrated the specific and direct interaction of Nanog and Oct4 
with the Esrrb gene. Thus I have identified Esrrb as a bona-fide target regulated by both 
Nanog and Oct4. Strikingly, short hairpin RNA (shRNA)-mediated Esrrb knockdown 
resulted in a loss of ES cell morphology, accompanied by a significant reduction of 
pluripotency markers and induction of differentiation genes.  Hence, the project 
uncovered the novel role of Esrrb in maintaining the undifferentiated state of mouse ES 
cells. To further characterize the function of Esrrb, the transcriptional regulatory network 
 vi
of Esrrb was constructed using genome-wide ChIP-sequencing technology and 
microarray profiling. Both ES cell-associated genes and differentiation-related genes 
were found to be bound and regulated by Esrrb. Thus Esrrb maintains pluripotency by 
promoting the expression of downstream self-renewal genes while simultaneously 
repressing the activity of differentiation-promoting genes. Furthermore, Nanog 
overexpression can rescue the differentiation phenotype induced by Esrrb depletion. 
Thus, Nanog is a key downstream target of Esrrb in maintaining pluripotency. In addition, 
Esrrb is involved in the regulation of genes encoding for chromatin modifiers, such as 
Jmjd3. This suggests a role for Esrrb in governing the unique chromatin structure of ES 
cells. Together, the findings in this thesis provide new insights into the mechanisms that 
underlie the critical roles of Nanog and Esrrb in maintaining the self-renewal and 
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Chapter I. Introduction 
Stem cells are defined by their unique capacity to self-renew and undergo multi-lineage 
differentiation. Stem cells can be found in both adult and embryonic tissues where they 
are important for the processes of cell regeneration, growth and embryo development. 
Based on their capacity in differentiation, stem cells in mammals can be grouped into 
three different types, including totipotent stem cells, pluripotent stem cells and 
multipotent stem cells. Totipotent stem cells can generate all cell types that comprise an 
entire organism including the placenta. This developmental potential is best exemplified 
by the fertilized zygote and the cells of the blastomeres up to the 8-cell stage. Pluripotent 
stem cells can differentiate into all cell types of the three germ layers of an organism. 
Examples of pluripotent stem cells include the embryonic stem (ES) cells, embryonic 
germ (EG) cells and embryonal carcinoma (EC) cells. Multipotent stem cells can give 
rise to cells of certain specialized lineages. Many adult stem cells are multipotent, 
including hematopoietic  stem cells, mesenchymal stem cells, and other adult progenitor 
cells.  
 
Pluripotent mouse ES cells are derived from the inner cell mass (ICM) of the E3.5 
(embryonic day 3.5) preimplantation embryo (Evans and Kaufman, 1981; Martin, 1981). 
Due to their similarity to the ICM cells, mouse ES cells are a good model for the study of 
embryogenesis and other developmental processes. In addition, the capability of directed 
differentiation in culture has made mouse ES cells a potential source for cell replacement 
therapy (Fujikura et al., 2002; Kyba et al., 2002; Li, et al., 1998). On the other hand, their 
amenability to genetic perturbation approaches allows mouse ES cells to be a powerful 
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platform for the study of gene function (Nichols et al., 1998; Avilion et al., 2003; Mitsui 
et al., 2003). However, despite the derivation of mouse ES cells more than 20 years ago, 
little is understood on how ES cells maintain their unique properties. Hence, insights into 
the molecular mechanisms underlying the self-renewal and pluripotency of ES cells are 
necessary to realize their clinical and scientific potentials.  
 
1.1. Sources and properties of pluripotent stem cells  
Pluripotent stem cells can be isolated from various embryonic sources. For instance, EC 
cells can be derived from teratocarcinomas, while ES cells and EG cells can be isolated 
from the ICM and the primordial germ cells (PGCs) respectively. Despite the varied 
sources of isolation and derivation, these pluripotent cells share the unique properties of 
self-renewal and broad differentiation capacities.  
 
1.1.1. Mouse embryonal carcinoma cells 
Mouse embryonal carcinoma (EC) cells are derived from the teratocarcinomas. 
Teratocarcinomas are malignant tumors commonly found in the gonads. Histologically, 
these tumors comprise of various somatic tissues, such as bone, hair and teeth, and they 
maintain the ability of rapid growth during repeated transplantation (Solter et al., 1970; 
Stevens, 1970; Solter, 2006). In 1964, Kleinsmith and Pierce showed that single cells 
from teratocarcinomas retain the capability of tumourigenesis and differentiation into 
multiple lineages when injected into mice. This finding suggests that unique stem cells 
reside in teratocarcinomas. Furthermore, transplantation of preimplantation mouse 
embryos or embryonic tissues to extra-uterine sites resulted in teratocarcinoma formation 
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(Solter et al., 1970; Stevens, 1970). This finding indicates the embryonic origin of 
teratocarcinoma stem cells. In 1974, the stem cells in teratocarcinomas were successfully 
isolated and defined as embryonal carcinoma (EC) cells (Martin and Evans, 1974).  
 
EC cells grow in tight colonies, and are able to proliferate indefinitely (Martin and Evans, 
1974) (Figure 1.1). The pluripotency of EC cells has been demonstrated by several 
experiments. Firstly, subcutaneous injection of EC cells resulted in teratocarcinoma 
formation (Martin and Evans, 1974).  Brinster further found that when reintroduced into 
the embryo, EC cells could participate in the processes of embryogenesis and contribute 
to chimera generation. These findings suggest that EC cells are similar to the resident 
epiblast cells in vivo and are receptive to cues in the microenvironment of the embryo 
(Brinster, 1974). In addition, Martin and Evans showed that EC cells can be used for 
embryoid body (EB) formation and produce derivatives of all three primary germ layers, 
including the endoderm, the mesoderm and the ectoderm (Martin and Evans, 1975a and 
b).  
 
Mouse EC cells are characterized by the expression of unique markers, which include 
alkaline phosphatase, SSEA1 (stage-specific embryonic antigen 1), TRA-1-60 antigen and 
TRA-1-81 antigen (Solter and Knowles, 1978; Kannagi, 1983). On differentiation, the 






However, it was soon apparent that EC cells suffer from many inherent limitations. Most 
EC cell lines have poor differentiation capacity and low efficiency in chimera generation. 
In addition, EC cells give rise to high incidences of tumor formation, thus limiting its 
application in generating live animals (Mintz and Illmensee, 1975; Papaioannou et al., 
1975; Illmensee and Mintz, 1976; Papaioannou et al., 1978; Stewart and Mintz, 1981; 
Stewart and Mintz, 1982; Rossant and McBurney, 1982). Moreover, EC cells are always 
aneuploid which prevents cells from proceeding through meiosis and producing mature 
gametes (Smith, 2001). Therefore, it was necessary to establish “true” stem cells that are 
isolated from the embryo and retain full developmental potential.   
 
1.1.2. Mouse embryonic stem cells 
Mouse embryonic stem (ES) cells were first derived from the inner cell mass and cultured 
on division-incompetent mouse fibroblasts in the presence of serum (Evans and Kaufman, 
1981; Martin, 1981). These cells have similar morphology to EC cells, but they grow in 
more compact colonies with a higher nucleus-cytoplasm ratio (Figure 1.2). The 
cytoplasmic organelles associated with non-apoptosis, such as autophagosomes, are also 
prevalent in mouse ES cells (Ginis et al., 2004).  
Figure 1.1 Mouse embryonal 
carcinoma cell line (Adapted 





The two most important properties of ES cells are self-renewal and pluripotency. The 
pluripotency of mouse ES cells has been demonstrated by extensive studies. In vitro, 
mouse ES cells can be induced to differentiate into various cell lineages (Doetschman et 
al., 1985; Nakano et al., 1994; Nishikawa et al., 1998). Upon injection into 
immunoincompetent mice, mouse ES cells can form teratomas consisting of all three 
germ layers (Evans and Kaufman, 1983). Furthermore, when ES cells are reintroduced 
into the preimplantation embryo, they can colonize all of the embryonic lineages and 
contribute to chimeras that give rise to viable offsprings (Bradley et al., 1984; 
Beddington and Robertson, 1989; Smith, 2001). Because of their superior differentiation 
capability, consistent chimera generation and normal diploid karyotype, ES cells 
represent a better model than EC cells for the study of embryogenesis and directed 
differentiation.   
 
At the molecular level, ES cells express many of the specific markers of EC cells. They 
include alkaline phosphatase, SSEA1 and TRA-1-60/81 antigen. Transcription factors, 
such as octamer-binding transcription factor-4 (Oct4), SRY-related HMG Box 2 (Sox2) 
and Nanog, are also highly expressed in ES cells (Table 1.1). 








Table 1.1 The characterized markers of ES cells (Adapted from Boiani and Schöler, 2005). 
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1.1.3. Mouse embryonic germ cells 
Compared with EC and ES cells, embryonic germ (EG) cells are the least-studied 
pluripotent stem cells. EG cells are derived from the primordial germ cells (PGCs) of the 
proximal epiblast during the E8.5 to E11.5 stages of the embryo (Matsui et al., 1992; 
Resnick et al., 1992; Durcova-Hills et al., 2006). During the initial stage of PGC culture 
to isolate EG cells, basic fibroblast growth factor (bFGF), leukemia inhibitory factor (LIF) 
and feeder layers secreting the transmembrane form of stem cell factor (SCF) are 
required. After the isolation process, however, EG cells can be cultured routinely under 
the same conditions with ES cells (Matsui et al., 1992; Dolci et al., 1991).  
 
EG cells are highly similar to ES cells. For instance, EG cells express alkaline 
phosphatase and SSEA1 antigen. They are immuno-reactive to TRA-1-60 and TRA-1-81. 
In culture, EG cells have similar morphology to ES cells and can self-renew while 
maintaining a normal karyotype. EG cells are also capable of giving rise to chimeras 
(Matsui et al., 1992; Labosky et al., 1994; Stewart et al., 1994). Furthermore, EG cells 
are capable of germ-line transmission (Labosky et al., 1994; Stewart et al., 1994). 
However, unlike ES cells, EG cells retain the erased imprinting pattern that was acquired 
during the process of germ cell development (Tada et al., 1997). For example, the 
insulin-like growth factor 2 receptor (Igf2r) gene shows different methylation status in 
EG cells from ES cells (Labosky et al., 1994). This erased imprinting pattern may 
compromise the developmental potential of EG cells (Kato et al., 1999; Tada et al., 1998). 
Kato et al. showed that transplantation of the EG cell nuclei into the enucleated oocyte 
resulted in formation of an abnormal placenta (Kato et al., 1999). In addition, 25-50% EG 
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cell-contributed chimeras were abnormal in weight and gross skeletal structure (Tada et 
al., 1998).   
 
1.1.4. Pluripotent stem cells derived from other species 
Pluripotent stem cells have been isolated from animal species other than the mouse. For 
examples, ES cells from human, horse, pig, dog and cat have been isolated (Thomson et 
al., 1998; Saito et al., 2002; Li et al., 2006; Hatoya et al., 2006; Serrano et al., 2006). 
Due to the scarcity of embryos and the lack of established cell recovery or culturing 
system, studies on pluripotent cells from other species have lagged significantly behind 
their mouse and human counterparts. 
 
Human EC cells were isolated from human teratocarcinomas (Hogan et al., 1977). 
Similar to mouse EC cells, human EC cells are capable of self-renewal and differentiation 
(Andrews et al., 1984). The chromosomes of human EC cells are also abnormal, which 
greatly limits their application in human cell-based therapy (Blelloch et al., 2004). At the 
molecular level, human EC cells and mouse EC cells have overlapping but distinct gene 
expression profiles. For instance, similar with mouse EC cells, human EC cells are 
positive for alkaline phosphatase staining and immuno-reactive for TRA-1-60 and TRA-
1-81. However, unlike mouse EC cells, human EC cells express SSEA3 and SSEA4 
instead of SSEA1. On differentiation, the expression of SSEA3 and SSEA4 is lost while 
the expression of SSEA1 turns on (Fenderson et al., 1987).  
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Human EG cells are derived from the gonadal tissue of the human embryo during the 5th-
11th week post-fertilization stages (Shamblott et al., 1998). During in vitro culture, 
human EG cells grow as tightly compacted colonies and are relatively resistant to 
enzymatic disaggregation. As a result, the efficiency of human EG cell culture and 
expansion is low. In addition, although they are grown on a feeder cell layer, human EG 
cells require FGF stimulation. Human EG cells have normal karyotype and high 
expression of pluripotent marker genes, such as SSEA-1, SSEA-4 and OCT4. 
 
Human ES cells were isolated almost 17 years after the first derivation of mouse ES cells 
(Evans and Kaufman, 1981; Martin, 1981; Thomson et al., 1998). Similar to mouse ES 
cells, human ES cells are isolated from the blastocysts and can grow in colony 
morphology (Thomson et al., 1998). However, the doubling time of human ES cells (35-
40 hours) is much longer than that of mouse ES cells (12 hours). Human ES cells are 
pluripotent based on their capacity for in vitro differentiation and teratoma formation. 
Notably, human ES cells can differentiate into the trophectoderm lineage while mouse ES 
cells typically do not (Gerami-Naini et al., 2003; Odorico et al., 2001; Thomson et al., 
1995, Xu et al., 2002, Rossant and Papaioannou, 1984). By comparing the expression 
patterns of five human ES cell lines and 69 different human somatic cell lines or tissue 
samples, Sperger et al. identified the highly expressed genes in human ES cells. These 
genes include OCT4, FOXD3, SOX2, DNMT3B, Frizzled 7/8, and TCF3 (Sperger et al., 
2003). In addition, the genes encoding fibroblast growth factor (FGF) receptors are also 
highly expressed. This suggests a potential role for the FGF signaling pathway in 
maintaining the undifferentiated state of human ES cells (Sperger et al., 2003).  Other 
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studies using different strategies were also performed in an attempt to identify the genes 
that are important for human ES cell maintenance (Brandenberger et al., 2004; Richards 
et al., 2004; Abeyta et al., 2004; Bhattacharya et al., 2004; Bhattacharya et al., 2005). 
Based on these studies, the list of genes enriched in human ES cells includes OCT4, 
SOX2, NANOG, REX1, DNMT3B, LIN28, TDGF1 and GDF3. 
 
Human and mouse ES cells have distinct but overlapping gene expression profile. The 
regulatory mechanisms underlying cell growth and proliferation also show some 
differences (Sato et al., 2003; Wei et al., 2005) (Table 1.1). Like mouse ES cells, human 
ES cells express alkaline phosphatase, TRA-1-60 antigen and TRA-1-81 antigen 
(Thomson et al., 1995; Thomson and Marshall, 1998). The expression of mouse ES cell-
associated genes such as Oct4, Sox2, Lefty, Utf-1 and Tdgf is also conserved in human ES 
cells. However, the similarity in gene expression profile between human ES cells and 
mouse ES cells are limited (Wei et al., 2005). For instance, human ES cells express 
SSEA3 and SSEA4 but not SSEA1, while mouse ES cells do not express SSEA3 or SSEA4 
but express SSEA1 instead. Human ES cells do not express LIF receptor (LIFR), STAT3, 
or JAK, while expressing high levels of FGF receptors. This is consistent with the 
requirement of the FGF signaling pathway in human ES cell culture (Brandenberger et al., 
2004; Wei et al., 2005). Moreover, many genes that are involved in the Wnt, TGFβ/BMP 
or other signaling pathways are differentially expressed between the human and mouse 




1.1.5. Mouse ES cells as a cell model to study the ES cell biology 
In this project, mouse ES cells were used as a cell model to understand the mechanisms 
underlying the maintenance of self-renewal and pluripotency. Compared with other 
pluripotent stem cells, mouse ES cells have outstanding advantages for the study of ES 
cell biology.  
 
First of all, mouse ES cells provide a universal cell source for the study of embryogenesis, 
gene function and directed differentiation. Because mouse ES cells are derived from the 
ICM and maintain the capability of integration into the developmental processes of the 
embryo (Beddington and Robertson, 1989), they are valuable as a surrogate for 
deciphering the pluripotency of the ICM cells and the subsequent steps of cell 
commitment during early development. On the other hand, when combined with gene-
targeting technology, mouse ES cells serve as an excellent “vector” to study the functions 
of genes in embryogenesis and other biological processes (Thomas and Capecchi, 1986; 
Kuehn et al., 1987; Doetschman et al., 1987; Thomas and Capecchi, 1987; Thompson et 
al., 1989; Smithies, 2005; Capecchi, 2005). Mice with thousands of specific targeted 
mutations have been created to decipher the importance of these genes. Recently, 
attempts have been made to drive directed differentiation of mouse ES cells using a 
combination of genetic manipulation, chemical induction and addition of growth factors 
and extracellular matrices (Wichterle et al., 2002; Kim et al., 2002; Li et al., 2003; 
Schmitt et al., 2004; Solter, 2006). This may contribute to generation of cells and tissues 
for replacement therapy. Hence, a better understanding of the biology of mouse ES cells 
is crucial for using stem cells in clinical applications.  
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Secondly, the lesson learnt from the study of mouse ES cells may be applied to improve 
the understanding of human ES cell biology. Due to ethical consideration and limited 
sources of human embryos, the study of human ES cells is severely restricted. However, 
the understanding of the roles of extracellular and intracellular signals in the maintenance 
of mouse ES cells holds promises to generate improved methodologies for maintenance 
and proliferation of human ES cells in vitro.  
 
Thirdly, compared to the ES cells from other mammalian species, mouse ES cells have 
the most established isolation method and in vitro culturing protocol. Moreover, unlike 
mouse ES cells, the properties of ES cells from other species have not been well defined. 
For example, because of ethical reasons, the pluripotency of human ES cells has not been 
demonstrated by the chimera generation and the tetraploid complementation experiment. 
 
1.2. Factors required for the maintenance of mouse ES cells  
The capacity of self-renewal and pluripotency distinguishes ES cells from other cell types. 
These unique properties are maintained by extra-cellular signals and intra-cellular 
regulators.  
 
1.2.1. Signaling pathways in mouse ES cells 
Through binding to cell-membrane receptors, extracellular factors can induce nucleus-
directed signaling pathways to modulate gene expression. In mouse ES cells, 
extracellular signals are required for cell growth and maintenance. Several signaling 
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pathways, such as the leukaemia inhibitory factor (LIF) signaling pathway, the bone 
morphogenetic protein (BMP) signaling pathway and the wingless-related MMTV 
integration site (Wnt) signaling pathway have been reported to be involved in the 
regulation of stem cell properties.  
 
1.2.1.1. The leukaemia inhibitory factor (LIF) signaling pathway 
When mouse ES cells were first isolated from the embryo, fibroblast feeder cells were 
used to support their growth in culture. Without the feeder cells, ES cells cannot be 
maintained in an undifferentiated state (Evans and Kaufman, 1981; Martin, 1981). This 
suggests that the feeder cells produce factors that prevent the differentiation of ES cells. 
Using fractionation strategies, the active component of the feeder cell conditioned 
medium was identified to be the leukaemia inhibitory factor (LIF). Furthermore, LIF-
deficient fibroblasts are not capable of supporting ES cells (Hooper et al., 1987; Smith et 
al., 1988; Williams et al., 1988; Thompson et al., 1989).  
 
LIF belongs to the interleukin-6 (IL-6) cytokine family that comprises IL-6, IL-11, 
oncostatin M (OSM), ciliary neutrophic factor (CNTF), cardiotrophin-1 (CT-1) and 
cardiotrophin-like cytokine (CLC). In many cell types, these cytokine family members 
share overlapping effects on gene expression. They also regulate apoptosis, proliferation 
and differentiation (Heinrich et al., 2003). In mouse ES cells, LIF functions through the 
direct binding to a transmembrane heterodimeric receptor which consists of LIF-receptor 
β (LIFRβ) and signal transducer glycoprotein 130 (gp130). Upon the formation of the 
trimeric complex, LIF-LIFR-gp130, tyrosine kinase Jak (Janus kinase) is activated 
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through phosphorylation and serves as a docking site for Stat3 (signal transducer and 
activator of transcription 3). This in turn results in phosphorylation and dimerization of 
Stat3. The phosphorylated Stat3 will then translocate into the nucleus and activate its 
downstream target genes to support the self-renewal of ES cells (Niwa et al., 1998). The 
role of Stat3 as the downstream effector of the LIF signaling cascade was further 
demonstrated by Matsuda et al. who created a chimeric protein of Stat3 fused with the 
ligand-binding domain of estrogen receptor. When ES cells were treated with 4-hydroxy 
tamoxifen (4-HT), an agonist of estrogen receptor, the chimeric Stat3 became dimerized. 
This dimerized chimeric Stat3 can maintain ES cells in the self-renewing condition 
independent of LIF (Matsuda et al., 1999). In addition, Myc, a downstream target of Stat3, 
can confer LIF-independence on ES cells when ectopically expressed (Cartwright et al., 
2005). 
 
Although the LIF-gp130-Stat3 signaling cascade is sufficient for the self-renewal of 
mouse ES cells (Yoshida et al., 1994; Niwa et al., 1998), there is no direct evidence to 
support its importance in early embryonic development. It was reported that although LIF 
and LIFR are expressed in the early embryo, both LIF-null and LIFR-null embryos can 
form normal ICM and further develop beyond the egg cylinder stage (Stewart et al., 1992; 
Li et al., 1995). In addition, Stat3-null and gp130-null mouse embryos can also survive 
beyond the blastocyst stage (Yoshida et al., 1996; Takeda et al., 1997). Further 
investigation has uncovered the in vivo role of the LIF signaling pathway during 
embryonic diapause. The embryo lacking gp130 fails to recover after diapause, owing to 
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the inability to maintain the epiblast (Nichols et al., 2001). This result suggests that the 
signaling through gp130 is essential to prolong the epiblast development. 
 
1.2.1.2. The bone morphogenetic protein (BMP) signaling pathway 
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor beta 
(TGFβ) family that is widely involved in cell proliferation, differentiation and apoptosis 
in the embryo and many cultured cell types (Massague, 1998). There are over 20 BMPs, 
and these proteins function through receptor-mediated intracellular signaling pathways 
(Mishina, 2003). There are two types of BMP receptors: type I (Alk2, Alk3, and Alk6) 
and type II (BmprII). Interaction between different receptors determines the specificity 
and outcome of the BMP functions (Mishina, 2003). Generally, the interaction between 
BMPs and their receptors results in phosphorylation of the downstream effectors, R-
Smads (receptor regulated Smad proteins) (such as Smad1, Smad5, or Smad8). Two of 
these phosphorylated R-Smads form a heterotrimer with a common Smad protein, Smad4. 
This heterotrimer translocates into the nucleus and regulates the expression of 
downstream target genes (Derynck and Zhang, 2003; Massague, 2000; Miyazono et al., 
2000; Moustakas et al., 2001; Shi and Massague, 2003). In parallel, BMP-receptor 
signaling can also activate the mitogen activated protein kinase (MAPK) pathway 
mediated by TGFh1 activated tyrosine kinase 1 (TAK1), a MAPKKK tyrosine kinase. 
Even though the mechanism of BMP-mediated TAK1 activation remains unclear, some 
studies have suggested that TAK1 binding proteins (TAB1, TAB2 and TAB3) and X-
linked inhibitor of apoptosis (XIAP) may be involved in this process (Derynck and Zhang, 
2003; Massague et al., 2000; Yamaguchi et al., 1999; Behrens, 2000; Ishitani et al., 2003; 
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Ishitani et al., 1999; Smit et al., 2004; Massague, 2003). In addition, the BMP signaling 
pathway was also reported to participate in cross-talk with other growth factor/cytokine-
mediated signaling to inhibit the Smad function through an unknown mechanism (Aubin 
et al., 2004; Kretzschmar et al., 1997a, b).  
 
The function of the BMP pathway in mouse ES cells was uncovered by the observation 
that even in the presence of LIF, mouse ES cells could not be propagated in a serum-free 
condition, and the cells underwent differentiation towards neuronal lineages (Ying et al., 
2003). Further study identified BMP as the important component in the serum that sustain 
the undifferentiated state of ES cells through cooperation with the LIF pathway (Figure 
1.3) (Ying et al., 2003). The LIF/gp130/Stat3 signaling cascade blocks mesoderm and 
endoderm differentiations but favors neuronal differentiation, while the BMP/Smad 
signaling pathway prevents the differentiation into neuroectoderm lineages through 
targeting the inhibitor of differentiation 2 (Id2) gene (Ying et al., 2003). This was further 
confirmed by the overexpression of Id2 gene which led to the inhibition of neuronal 
differentiation of ES cells independent of the BMP signaling pathway (Ying et al., 2003).  
 
In the embryo, BMP is widely expressed during germ cell specification and body 
patterning (Chen et al., 2004; Nohe et al., 2004). However, BMP4-null or Smad4-null 
mouse embryos can still develop beyond the blastocyst stage with normal formation of 
the ICM (Fujiwara et al., 2001). 
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1.2.1.3. The wingless-related MMTV integration site (Wnt) signaling pathway 
The Wnt signaling pathway is critical for animal development (Cardigan and Nusse, 
1997). Recent work has reported the palmitoylation of Wnt3a at the conserved cysteine, 
Cys77. This modification seems to be crucial for its signal activation (Willert et al., 
2003). The Wnt signaling pathway is activated upon the binding of the Wnt protein to the 
Frizzled receptor on the cell surface. This binding leads to the inactivation of the 
downstream glycogen-synthase kinase-3 (GSK3) protein via the replacement of GSK3 
from the axin/adenomatous polyposis coli (APC) complex. The replacement of GSK3 in 
Figure 1.3 Major signaling pathways and transcription factors in maintaining the 
undifferentiated state of mouse ES cells. LIF and BMP cooperate to maintain the self-
renewal and pluripotency of ES cells. LIF activates STAT3, which blocks non-
neuronal differentiation. BMP inhibits neuronal differentiation by the induction of 
Smad1, 5, 8 and Id proteins. Activin/Nodal pathway promotes the proliferation of ES 
cells through the activation of Smad2/3. Oct4, Sox2 and Nanog are three key 
transcription factors in ES cells. They cooperate to block differentiation and promote 
self-renewal of ES cells (Adapted from Yamanaka et al., 2008). 
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turn prevents the degradation of β-catenin, which promotes its translocation into the 
nucleus where it associates with the T-cell factor/lymphoid enhancer factors (Tcf/Lef) to 
regulate gene expression (Moon, et al., 2002; Van et al., 2003).  
 
The involvement of the Wnt pathway in stem cell maintenance has been investigated by 
several studies. Sato et al. demonstrated that activation of the Wnt pathway is sufficient 
to support the self-renewal of both human and mouse ES cells (Sato et al., 2004). In their 
study, ES cells were treated with the GSK3 inhibitor, 6-bromoindirubin-3’-oxime (BIO), 
to activate the Wnt pathway, and the cells became resistant to the differentiation. 
Moreover, the BIO-treated mouse ES cells sustained the expression of pluripotent genes, 
such as Rex1, in the absence of LIF (Sato et al., 2004). However, BIO-induced inhibition 
of GSK3 mimics the effects of PI3K activation in the LIF signaling pathway (Paling et al., 
2004). In addition, the suppressed GSK can result in up-regulation of Myc, a key 
downstream target of the LIF pathway (Cartwright et al., 2005). Hence, the Wnt pathway 
may maintain the self-renewal of mouse ES cells through a synergistic effect with the 
LIF/Stat3 signals. More studies have reported the involvement of the Wnt pathway in ES 
cell biology. Ogawa et al. demonstrated that the Wnt pathway is important in maintaining 
the pluripoteny of mouse ES cells (Ogawa et al., 2006). Inactivating the APC complex or 
elevating β-catenin level results in the inhibition of neuronal differentiation (Haegele et 
al., 2003). In addition, activating the downstream target genes of the Wnt pathway, for 
example cyclin-D1, Myc and Bmp, can partially prevent mouse ES cells from neuronal 
differentiation induced by the BMP4 antagonist Noggin (He, et al., 1998; Shtutman et al., 
1999; Haegele et al., 2003).  
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1.2.1.4. Other signaling pathways 
Besides the LIF, BMP and Wnt signaling pathway, recent studies have uncovered other 
signaling pathways involved in ES cell maintenance. These pathways include the 
Activin/Nodal pathway and the Notch signaling pathway (Amit, et al., 2004; Ogawa et 
al., 2007; Louvi and Artavanis-Tsakonas, 2006). In ES cells, the Activin/Nodal pathway 
is autonomously activated to promote self-renewal (Figure 1.3). Inhibition of this 
pathway can dramatically decrease the proliferation of ES cells. On the other hand, 
serum-free culture supplemented with recombinant Activin or Nodal enhances the 
propagation of ES cells (Ogawa et al., 2007). The Notch signaling pathway is involved in 
cell-fate commitment through mediating cell-cell interactions in many tissues (Lai, 2004). 
In ES cells, interference of the Notch pathway through pharmacologic or genetic 
manipulation suppresses differentiation towards the neuronal lineages. Activation of the 
Notch pathway, in contrast, promotes cell differentiation towards the neuronal lineage 
(Lowell et al., 2006). Although these signaling pathways play potential roles in mouse ES 
cell maintenance, the mechanisms underlying their function remain relatively unclear.  
 
1.2.2. Transcription factors in ES cell maintenance 
In ES cells, signaling pathways play important roles in maintaining self-renewal and 
pluripotency. In most cases, these signaling pathways function through regulating gene 
expression by transcription factors. Extensive studies have shown that transcription 
factors, Oct4, Sox2 and Nanog, play critical roles in maintaining the undifferentiated 
state of mouse ES cells through regulating gene expression. 
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1.2.2.1 Transcription factor Oct4 
Oct4, also known as Oct3/4 or Pou5f1, belongs to the POU (Pit-Oct-Unc) transcription 
factor family. Oct4 regulates gene expression through its binding to the octamer motif, 
AGTCAAAT.  The DNA binding domain of Oct4 is divided into two regions (Figure 1.4), 
the POU-specific domain (POUs) and POU homeo-domain (POUh). The POUs and 
POUh domains are separated by the flexible linker residues that enable both domains to 
interact with DNA independently. In addition, these two domains may serve as 
interaction sites for cell type-specific co-regulators (Brehm et al., 1997). Subsequent 
studies have revealed that the POU-domains are central to the interaction of Oct4 and 
Sox2 via the HMG domain of Sox2 (described in greater detail in later section). Two 
other regions of Oct4, the N-terminal domain and the C-terminal domain are not 
responsible for the DNA-binding property of Oct4. Instead, these two domains are 
involved in the process of transcription regulation through their transactivation activities 










Figure 1.4 Schematic diagram illustrating the protein structure of Oct4 (Adapted from 
Pan et al., 2002).  
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Oct4 is expressed throughout the early embryo. Its expression is initially detected in the 
unfertilized egg, the totipotent zygote and all blastomeres at the cleavage stage (Schöler, 
1991). At the blastocyst stage, Oct4 expression starts to be restricted to the ICM, 
embryonic ectoderm and primordial germ cells (PGCs) (Palmieri et al., 1994). Other 
lineage cells including trophectoderm (TE), primitive endoderm and extraembryonic 
tissues have limited expression of Oct4 (Palmieri et al., 1994). In vitro, Oct4 is highly 
expressed in pluripotent cell lines such as ES cells, EG cells and EC cells (Rosner et al., 
1990; Pesce et al., 1998; Nichols et al., 1998).  
 
Genetic studies uncovered the critical roles of Oct4 in pluripotent cell lines and early 
development of the embryo. Oct4-null embryo dies as early as 3.5 days post coitum 
(d.p.c.) and showed blastocyst-like structures that are composed of trophectoderm lineage 
cells without the ICM. This indicates the importance of Oct4 for ICM formation while 
suggesting its inhibitory role towards trophectoderm differentiation (Nichols et al., 1998). 
Niwa et al. demonstrated that Oct4 controls pluripotency in a dose-dependent manner 
(Niwa et al., 2000). A two-fold induction of Oct4 led to ES cell differentiation into 
primitive endoderm and mesoderm. Loss of Oct4, on the other hand, triggered the 
differentiation into trophectoderm lineages (Figure 1.5). These observations indicate that 












Given its critical role in sustaining the developmental potential of ES cells and the early 
embryo, the activity of Oct4 gene is tightly regulated to ensure proper differentiation and 
continuity of the germline. Expression of Oct4 is controlled through its proximal 
promoter and two enhancer regions (the distal enhancer [DE] and proximal enhancer [PE] 
regions) (Yeom et al., 1996). Comparative study between species has identified four 
highly conserved regions (CR) 1-4 at the regulatory region of Oct4 (Nordhoff et al., 
2001). CR1 is located in the immediate upstream region of exon 1, while CR2, CR3 and 
Figure 1.5 Oct4 functions in a dose-dependent manner to control pluripotency in ES 
cells. Increasing or reducing Oct4 level in ES cells lead to the loss of pluripotency and 
differentiation into primitive endoderm and trophectoderm lineages respectively. 
These observations indicate that appropriate Oct4 expression level is necessary for the 
maintenance of pluripotency (Adapted from Niwa, 2001). 
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CR4 overlap with DE and PE (Figure 1.6). Multiple transcription factors have been 
identified to regulate the expression of Oct4 by binding to the conserved regions. Germ 
cell nuclear factor (Gcnf) has been reported to be a repressor of Oct4 through targeting 
the PE region (Hummelke and Cooney, 2001; Fuhrmann et al., 2001). In the embryo, loss 
of Gcnf resulted in the mis-repression of Oct4 in germ layer cell lines after gastrulation 
(Fuhrmann 2001). Cdx2 is another repressor of Oct4. Cdx2 directly binds to the Oct4 
CR4 region and inhibits Oct4 in a reciprocal fashion (Niwa et al., 2005). Several 
transcription factors have also been reported to activate the expression of Oct4. They 
include Oct4, Sox2 and Sall4 (Chew et al., 2005; Zhang et al., 2006).  Oct4 expression is 
also regulated by epigenetic modifications. It has been reported that extinction of Oct4 
activity is correlated with the methylation of the PE and DE elements at the Oct4 
promoter/enhancer regions (Ben-Shushan et al., 1993). This is consistent with the 
observation that de novo methylation during embryonic development accompanies the 
loss of Oct4 expression in somatic cells (Jaenisch, 1997). More specifically, Feldman et 
al. found that G9a, a histone H3 lysine 9 methyltransferase represses Oct4 expression by 











As a transcription factor, Oct4 has been reported to bind to several target genes to 
regulate their expression. These genes include Oct4, Sox2, Fbx15 (F-box containing 
protein 15), Rex1/Zfp42 (Zinc finger protein 42), Utf1 (undifferentiated cell transcription 
factor 1), Opn and Fgf4 (fibroblast growth factor 4) (Chew et al., 2005; Tokuzawa et al., 
2003; Catena et al., 2004; Nishimoto et al., 1999; Botquin et al., 1998; Ambrosetti et al., 
2000; Dailey et al., 1994; Yuan et al., 1995).  
 
1.2.2.2 Transcription factor Sox2 
Sox2 (SRY-related HMG box) belongs to the Sox gene family that encode for HMG-
domain containing transcription factors. In the early embryo, Sox2 can be detected in the 
zygote and its expression is maintained throughout the cleavage, blastocyst and epiblast 
stages (Avilion et al., 2003). However, unlike Oct4, Sox2 expression can also be detected 
in the extraembryonic ectoderm and neuroectoderm (Avilion et al., 2003). The relatively 
wider expression profile of Sox2 indicates that its function may not be restricted to 
DE PE
Exon1~100 bp  
Figure 1.6 A schematic diagram illustrating the regulatory elements of the Oct4 
promoter and enhancer regions. Distal enhancer (DE) and proximal enhancer (PE) 
are two enhancer regions important for Oct4 expression. Four highly conserved 
regions (CR) (CR1-4) are found located in the proximal promoter, DE and PE 
regions (Adapted from Pan et al., 2002). 
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pluripotent stem cells. Sox2-null embryo dies at 5.5 d.p.c due to the lack of epiblast 
(Avilion et al., 2003). In ES cells, depletion of Sox2 results in polyploidy and 
differentiation into trophectoderm lineage (Chew et al., 2005; Li et al., 2007). These 
results implicate the essential roles of Sox2 in embryogenesis and ES cell maintenance.  
 
The overlapping expression profiles between Oct4 and Sox2 suggest a close functional 
relationship. Sox2 is capable of heterodimerizing with Oct4 to form a ternary complex on 
the Fgf4 gene (Yuan et al., 1995). Other known targets of Oct4, such as Fbx15, Rex1, 
Utf1, Opn and Nanog, are also bound by Sox2 (Tokuzawa et al., 2003; Nishimoto et al., 
1999; Botquin et al., 1998; Kuroda et al., 2005; Rodda et al., 2005). Interestingly, Oct4 
and Sox2 function as a binary complex to regulate the expression of their own encoding 
genes (Catena et al., 2004; Okumura-Nakanishi et al., 2005; Chew et al., 2005).  
 
1.2.2.3. Transcription factor Nanog 
Nanog was first identified as “ENK” (early embryo specific NK) based on the homolog 
of its homeodomain to NK protein family (Wang et al., 2003). The two studies by 
Chambers et al. and Mitsui et al. uncovered its critical roles in ES cell maintenance and 
embryonic development (Chambers et al., 2003; Mitsui et al., 2003).  
 
The Nanog protein comprises three domains, N-terminal domain, homeodomain, and C-
terminal domain. The N-terminal domain has 96 amino acids and is serine-rich with 
transactivation activity (Pan and Pei, 2003) (Figure 1.7). The C-terminal domain 
comprises a CD2 region and 10 WR repeats which are highly conserved between human 
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and mouse. Compared with the N-terminal domain, the C-terminal domain has a much 
higher transactivation activity (Pan and Pei, 2003) (Figure 1.7). The homeobox domain is 
a DNA binding domain with low similarity with the other members of the NK family.  
 
Nanog has a highly restricted expression profile. Its expression is elevated in 
undifferentiated ES cells, EG cells and EC cells but is not detected in differentiated cells 
(Chamber et al., 2003; Mitsui et al., 2003). In the embryo, Nanog is first detected at the 
morula stage, and its expression persists throughout the blastocyst stage after which it 
starts to decline. At the post-implantation stage, Nanog expression is maintained in the 
primordial germ cells and in the subsets of the epiblast cells.  During primitive streak 
formation, the expression of Nanog is down-regulated (Chambers et al., 2003; Mitsui et 
al., 2003; Hart et al., 2004).  
 
Nanog-null embryo fails in the formation of primitive ectoderm, and dies at 4.5 d.p.c,. 
Hence, Nanog is required for the ICM formation and primitive ectoderm development 
(Mitsui et al., 2003). ES cells derived from Nanog -/- ICM differentiate into endoderm 
lineage cells (Chambers et al., 2003; Mitsui et al., 2003; Hatano et al., 2005). 
Interestingly, overexpression of Nanog allows ES cells to bypass its dependence on the 
LIF and BMP signaling pathway (Chambers et al., 2003; Mitsui et al., 2003). These 
results demonstrate the indispensable roles of Nanog in early embryonic development 







Several regulators have been implicated in the regulation of Nanog expression (Figure 
1.8). By the Chromatin Immunoprecipitation (ChIP) assay and the electrophoretic 
mobility shift assay, the Oct4/Sox2 complex was shown to bind to the sox-oct element in 
the proximal promoter of the Nanog gene (Rodda et al., 2005; Kuroda et al., 2005). 
Recently, FoxD3 was shown to bind to the promoter region of Nanog and activate its 
expression (Pan et al., 2006) (Figure 1.8). Besides these factors which activate its 
expression, Nanog was also found to be directly regulated by repressors. The tumour 
suppressor p53 binds to the promoter of Nanog, thereby enabling p53-dependent 
suppression of Nanog expression during differentiation (Lin et al., 2005). Tcf3, a 
downstream effector of the Wnt pathway, is another transcription regulator found to 
negatively regulate Nanog expression (Pereira and Merrill, 2006). Ablation of Tcf3 in ES 







Figure 1.7 A schematic diagram showing the protein structure of Nanog (Adapted 
from Pan and Pei, 2003).   
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1.2.2.4. Nuclear receptor proteins 
Nuclear receptor proteins are transcription factors that respond to extracellular signals 
(Evans, 1988; Green and Chambon, 1988; Beato, 1989). Generally, they contain distinct 
domains A to F that exhibit different functions (Laudet et al., 1992; Glass, 1994; 
Bourguet et al., 1995). For example, domain C is a DNA-binding domain, while domain 
E has multiple functions including ligand binding, transactivation and dimerization 
(Glass, 1994; Bourguet et al., 1995). Nuclear receptor proteins are divided into four 
classes according to their interaction with heat-shock proteins, their tendency to form 
dimers and DNA-binding specificity, class I nuclear receptor proteins consist of the 
steroid receptor proteins with larger A and B domains. They include estrogen receptors 
Figure 1.8 Genetic regulation of Nanog transcription. Oct4/Sox2 complex and FoxD3 
activate Nanog expression by binding to the proximal promoter. TCF3 and p53 are 
involved in repression of Nanog expression. STAT3 from the LIF pathway and T from 
BMP pathway may also be involved in Nanog regulation (Adapted from Pan and 
Thomson, 2007). 
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(ERs), glucocorticoid receptors (GRs), androgen receptors (ARs), progestin receptors 
(PRs) and mineralocorticoid receptors (MRs).  These proteins are sequestered in 9S 
heterocomplexes containing heat-shock proteins, immunophilins and other chaperons 
(Pratt and Toft, 1997; Knoblauch and Garabedian, 1999). Upon binding of ligands to 
these receptors, the protease-resistant conformation of the complexes is altered. This 
results in the dissociation of the chaperons along with the dimerization of the receptor 
proteins (Pratt and Toft, 1997; Knoblauch and Garabedian, 1999; Dechering et al., 2000). 
The class II receptors consist of thyroid hormone (TR), dihydroxyvitamin D3 receptors 
(VDR), all trans-retinoic acid receptors (RAR), 9 cis retinoic acid receptors (RXR), and 
most of the orphan receptors. Unlike the class I receptors, members of the class II 
receptors have shorter A and B domains that do not interact with heat-shock proteins. In 
the absence of ligands, class II receptor proteins form heterodimers with RXR. Upon 
activation by the ligands, the receptor proteins in turn form homodimers or occasionally 
monomers to regulate gene expression (Brtko, 1994; Parker, 1995). Class III nuclear 
receptors mainly regulate transcription as monomers. Steroidogenic factors belong to this 
class of proteins. The class IV receptors share the properties of both class I and II 
receptor proteins and bind DNA exclusively as monomers (Jiang et al., 1997). Some 
orphan nuclear receptor proteins such as hepatocyte nuclear factor 4 (HNF-4) belong to 
this class of nuclear receptors (Jiang et al., 1997). Similar to other receptor proteins, 
nuclear receptors can respond rapidly to extra-cellular signals and function in maintaining 
or altering the physiological state of cells. Generally, the receptors are modified by the 
binding of their ligands, which increases the receptor binding affinity for their specific 
DNA recognition sequences, termed responsive elements (RE), resulting in the 
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modulation of gene transcription (Laudet, 1997; Zhang et al., 2004; Tsai and O’Malley, 
1994; Mangelsdorf et al., 1995).  
 
Many nuclear receptors have been shown to be involved in embryonic development and 
maintenance of ES cells. They include Hepatocyte nuclear factor 4α (HNF4a), Germ cell 
nuclear factor (Gcnf), Nuclear receptor subfamily 0, group B, member 1 (Nr0b1)  and 
Liver receptor homologue 1 (LRH-1/Nr5a2) (Chen et al., 1994; Duncan et al., 1997; 
Chung et al., 2001; Fuhrmann et al., 2001; Gu et al., 2005; Mitsui et al.,  2003; Clipsham 
et al., 2004; Palmqvist et al., 2005; Niakan et al., 2006; Pare et al., 2004). HNF4a is the 
earliest nuclear protein to be expressed in vertebrate embryos and is a marker of primitive 
endoderm (Duncan et al., 1997). HNF4a-null mouse embryo dies at E6.5 because of 
apoptosis in the embryonic ectoderm (Chen et al., 1994). HNF4a-/- mouse ES cells can 
only give rise to the endoderm lineages, suggesting its repressive effect on endoderm 
differentiation (Duncan et al., 1997). The repressive role of HNF4a in the endoderm was 
further confirmed by the finding that Gata6, an endoderm marker, regulates HNF4a 
expression in the visceral endoderm (Morrisey et al., 1998). Gcnf is another nuclear 
receptor with critical roles in embryonic development. The Gcnf-null mice show 
embryonic lethality due to cardiovascular complications, neural tube closing and 
posterior truncation defects (Chung et al., 2001). Gcnf was reported to be a repressor of 
Oct4 (Fuhrmann et al., 2001; Gu et al., 2005). Nr0b1 belongs to the orphan nuclear 
receptor proteins, and has a recognized role in the establishment and maintenance of 
steroid producing tissues and steroidogenesis (Morohashi, 1997; Keegan and Hammer, 
2002). In mouse ES cells, it is among the top 20 most highly expressed genes (Mitsui et 
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al., 2003). Its expression is, however, significantly down-regulated with the 
differentiation of ES cells (Mitsui et al., 2003; Clipsham et al., 2004; Palmqvist et al., 
2005). siRNA-mediated knockdown or conditional knockout of Nr0b1 led to ES cell 
differentiation into endoderm-like lineages (Niakan et al., 2006). LRH-1 is also known as 
fetoprotein transcription factor (FTF). It is an orphan nuclear receptor, and is highly 
expressed in the pluripotent cells (Gu et al., 2005; Pare et al., 2004). It can also be 
detected in the endoderm-derived tissues such as the liver, pancreas, and intestine 
(Annicotte et al., 2003; Nitta et al., 1999; Rausa et al., 1999).  LRH-1 null embryo dies at 
E6.5 to E7.5 due to the mis-regulation of endodermal genes (Pare et al., 2004; Gu et al., 
2005). LRH-/- ES cells have similar morphology to wild type ES cells but their Oct4 
levels are more rapidly down-regulated upon LIF withdrawal-induced differentiation (Gu 
et al., 2005). LRH-1 was reported to play a role in regulating the expression of Oct4 in 
ES cells and in the embryo (Gu et al., 2005). Disruption of LRH1 resulted in loss of Oct4 
expression both in vivo and in vitro (Gu et al., 2005), indicating the essential roles of 
LRH1 in maintaining Oct4 expression. Its role in activation of Oct4 expression was 
confirmed by the direct binding of LRH1 to the Oct4 proximal enhancer and promoter 
(Gu et al., 2005). However, because LRH-1-null embryo dies at a later stage than Oct4-
null embryo, LRH-1 may not be required for the Oct4 expression in the ICM. Rather, 
LRH-1 is required for Oct4 expression in the epiblast. On the other hand, LRH-1 may 
function through the Wnt signaling cascade to maintain self-renewal, given to the similar 
phenotypes of the β catenin- and LRH-1-inactivated embryos (Huelsken et al., 2000). 
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Besides HNF4a, Gcnf, Nr0b1 and LRH-1, other nuclear receptor proteins, such as 
peroxisome proliferators-activated receptor γ (PPARγ), Retinoid acid receptors (RA), 
Chicken ovalbumin upstream promoter transcription factors (COUP-TFs) and 
Steroidogenic factor (SF1/Nr5a1), are also important for embryonic development (Barak 
et al., 1999; Lohnes et al., 1994; Mendelsohn et al., 1994, Kastner et al., 1994; Durston 
et al., 1989; Saga et al., 1999; Kastner et al., 1994; Sucov et al., 1994; Massaro et al., 
2003; Matt et al., 2003; Romand et al., 2002; Wendling et al., 2001; Qiu et al., 1997; 
Pereira et al., 1999; Luo et al., 1994; Luo et al., 1995; Sadovsky et al., 1995).  
 
1.3. Genetic perturbation and genomic approaches to understand ES cell biology 
To achieve a detailed understanding of the transcription regulatory network in mouse ES 
cells, we need to identify the regulatory targets of transcription factors, uncover the cis-
regulatory element in the genome and investigate the combinatorial control of gene 
expression by multiple transcription factors. In order to address these challenges, genetic 
perturbation combined with genomic approaches have been developed and extensively 
applied in the study of ES cell biology.    
 
1.3.1. Alteration of gene expression by genetic perturbation  
There are two main strategies of genetic perturbation used for the study of ES cell 
biology. They are the ‘gain-of-function’ approach and the ‘loss-of-function’ approach. 
Most gain-of-function studies involve introducing the cDNA of a gene into cells, ideally 
resulting in the hyper-activation or hyper-repression of the downstream effectors 
regulated by the gene product. These studies can be used to study the function of a gene 
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and dissect the regulatory network in the ES cell biology. For instance, overexpression of 
Nanog in mouse ES cells renders the cells independent of the LIF and BMP signals 
(Mitsui et al., 2003; Chambers et al., 2003; Ying et al., 2003). Through the analysis of 
expression arrays performed on these cells, the modulators regulated by Nanog can be 
identified and the interconnection of Nanog with the LIF and BMP signals can be 
dissected. One of the potential applications of the gain-of-function approaches is to 
identify a gene whose expression is specific for a certain cell lineage. For example, 
elevating the expression of Gata4 or Gata6 drives ES cells to the primitive endoderm 
lineage, suggesting a role of these two genes in endoderm differentiation (Fujikura et al., 
2002; Capo-Chichi et al., 2005). On the other hand, the gain-of-function approaches have 
been used for directed cell differentiation through overexpressing lineage-specific genes 
(Kyba et al., 2002; Li et al., 1998). However, one caveat with these approaches is that 
they rely on the assumption that over-expression of a gene is sufficient to induce its 
downstream activity. This assumption may not be universally true because the protein 
may not carry the appropriate post-translational modifications or have the correct 
subcellular localization and as a result may be inactive despite its overexpression. 
 
‘Loss of function’ approaches are classic means of elucidating gene function through 
suppressing the expression of specific genes. These approaches include homologous 
recombination, RNA interference (RNAi) technology and other gene-perturbing 
strategies such as random insertional mutagenesis and ribozymes and antisense RNA 
methodology. Homologous recombination is the most direct way to assess gene function 
through the deletion of the gene at the DNA level in the genome. This approach is highly 
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effective, but is slow and labour-intensive. RNAi technology is a reliable tool used to 
generate loss-of-function phenotypes transiently or stably in mammalian cells with 
precision and ease. RNAi-mediated gene suppression can be induced by introducing 
chemically synthesized small interfering RNAs (siRNAs) or plasmids expressing short 
hairpin RNAs (shRNAs) into cells. The siRNAs introduced or produced from shRNAs by 
Dicer are incorporated into the RNA-induced silencing complex (RISC) to direct 
sequence-specific degradation or translational suppression of the target mRNA (Bernstein 
et al., 2001; Dykxhoorn et al., 2003). Moreover, the recent development of inducible 
RNAi systems has allowed knockdown of a gene in a temporally and spatially regulated 
manner (Dickins et al., 2005; Ngo et al., 2006). Despite the efficiency of RNAi 
technology in the study of gene function, it remains difficult to consistently predict the 
capability of RNAi constructs in gene knockdown. In addition, RNAi constructs 
introduced may induce ‘off-target’ effect which suppresses genes other than the intended 
target. To avoid this, at least two independent RNAi constructs and RNAi-immune cDNA 
rescue experiments are recommended. Both recombination-mediated gene deletion and 
siRNA-mediated gene knockdown have been widely used to identify the genes critical for 
ES cell maintenance and embryonic development, such as Oct4, Sox2, Nanog, Mbd3 
(Nichols et al., 1998; Avilion et al., 2003; Chambers et al., 2003; Mitsui et al., 2003; Kaji 
et al., 2006). Random insertional mutagenesis and ribozymes and antisense methodology 
are also useful tools to elucidate gene function but are less amenable to automation or 




1.3.2. Genomic approaches to study gene expression in ES cells  
To have a comprehensive understanding of the molecular events in the regulatory 
networks in ES cells, systematic approaches have been developed to analyze the 
expression and regulation of genes on a genome-wide scale.  
 
Expression profiling approaches include expressed sequence tags (ESTs), differential 
display, serial analysis of gene expression (SAGE), massively parallel signature 
sequencing (MPSS), large-scale in situ hybridization and microarray analysis (Adams et 
al., 1991; Liang et al., 1992; Schena et al., 2000; Brenner et al., 2000; Komiya et al., 
1997; Hughes and Shoemaker, 2001; Lipshutz et al., 1999; Schena et al., 1995). The EST 
data mining techniques are used to identify novel genes through digital differential 
display (DDD) analysis or in silico subtraction analysis. Several ES cell specific genes 
(such as Nanog, Eras and Sox15) have been identified by using the EST data mining 
techniques (Mitsui et al., 2003; Takahashi et al., 2003; Maruyama et al., 2005). 
Differential display techniques, including polymerase chain reaction (PCR)-based 
differential display and suppression subtractive hybridization, are used for novel gene 
identification (Liang and Pardee, 1992; Diatchenko et al., 1996). For instance, Hllnagel et 
al. showed the inducd expression of the Id genes (Id1, Id2 and Id3) by BMP2/4 in mouse 
ES cells by using PCR-based differential display analysis, while Zeng et al. identified 50 
oocyte-specific genes (Such as Tcl1, Zp1 and Bmp15) through suppression subtractive 
hybridization analysis (Hllnagel et al., 1999; Zeng et al., 2003). Both SAGE and MPSS 
are sequence-based expression analyses and promise a qualitative and quantitative 
characterization of the transcriptome in cells (Velculescu et al., 1995; Brenner et al., 
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2000). A series of genes have been identified by the SAGE or MPSS analysis for their 
potential roles in ES cell maintenance (Anisimov et al., 2002; Richards et al., 2004; Wei 
et al., 2005; Miura et al., 2004). For instance, 192 genes, including OCT3/4, NANOG, 
SOX2, REX1 and GDF3, were identified to be up-regulated in human ES cells by SAGE 
analysis (Richards et al., 2004). Large-scale in situ hybridization is a useful technique to 
detect the expression patterns of genes in embryos or ES cells (Neidhardt et al., 2000; 
Gitton et al., 2002; Reymond et al., 2002; Yoshikawa et al., 2006). Microarray analysis 
can be used to monitor the mRNA levels of genes in a parallel fashion for many cell 
samples at the same time (Schena et al., 1995; Schena et al., 1996; Lockhart et al., 1996; 
DeRisi et al., 1997). In the study of ES cells, microarray analysis has become a routine 
strategy to detect gene expression profiles. For example, using Affymetrix microarrays, 
Ramalho-Santos et al. compared the expression profiles between ES cells, 
hematopoietic stem cells and neural stem cells.  
 
Gene expression profiling analyses provide information about the product of the 
regulatory events impinging on the expression of genes. It is of interest to understand 
how regulatory proteins control gene activity. This can be addressed by chromatin 
immunoprecipitation (ChIP) assay. The ChIP assay was first described by Solomon et al. 
and has been used extensively for the study of protein/DNA interactions in living cells 
(Solomon et al., 1988). The assay comprises three main steps which include cross-linking 
of the proteins to DNA by formaldehyde, co-immunoprecipitating the protein-DNA 
fragments using a specific antibody against the protein of interest, and recovery of the 
immunoprecipitated DNA for sequence determination (Figure 1.9). ChIP can be 
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combined with paired-end ditag (PET) technology (ChIP-PET) or DNA microarray 
(ChIP-chip) to achieve genome-wide mapping of the ChIP-enriched DNA fragments. 
These strategies allow identification of binding sites of transcription regulators or 
chromatin-associated modifications on a global scale. In the ChIP-PET assay, the 
enriched DNA generated by ChIP is labeled by a pair of signature tags at the 5’ and 3’ 
ends. The paired-end ditags (PETs) are sequenced and mapped to the genome to 
demarcate the transcription boundaries of every gene (Ng et al., 2005; Wei et al., 2006). 
In the ChIP-chip approach, ChIP-enriched DNA and non-enriched control DNA are 
labeled with Cy5 and Cy3 dyes respectively before being hybridized to a DNA 
microarray. The regions enriched with Cy5 signals relative to Cy3 signals inferred to be 
bound by the transcription factor of interest (Buck and Lieb, 2004; Mockler et al., 2005). 
Both the ChIP-PET assay and the ChIP-chip assay can be used for genome-wide location 
mapping. Moreover, combined with computational algorithms, these approaches can also 
be applied to decipher and characterize the DNA-binding motif of a transcription factor. 
Computational algorithms have been designed to identify DNA-binding motif pairs of 
different transcription factors which may account for the co-regulation of specific genes 
by these transcription factors (Pilpel et al., 2001). However, in spite of the successful 
application of these two approaches, the ChIP-PET and ChIP-chip assay have limitations. 
For examples, these two approaches require large amounts of DNA and they are 
expensive. Recently, a new genomic mapping technology, the ChIP-sequencing method 
(ChIP-Seq), has been developed (Barski et al., 2007; Johnson et al., 2007; Mikkelsen et 
al., 2007; Robertson et al., 2007). This technique combines ChIP assay with massively 
parallel DNA sequencing of the ChIP-enriched DNA. Compared with ChIP-PET and 
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ChIP-chip, ChIP-sequencing technology is more sensitive and less expensive. By using 
the Solexa sequencing technology, several groups have successfully performed genome-
wide mapping studies to detect the binding sites of transcription factors and the 
distribution of epigenetic modifications throughout the genome (Barski et al., 2007; 





1.4. Objective and value of this project 
ES cells offer great potential for regenerative medicine. As a result, there are tremendous 
interests in better understanding of the regulatory mechanisms that govern ES cell 
Figure 1.9 Schematic diagram depicting the process of ChIP. Cells are treated with 
formaldehyde to cross-link the proteins with the DNA, which are further sheared by 
sonication to produce soluble chromatin. Using antibody against a protein of interest, 
the protein-bound DNA fragments are selectively coimmunoprecipitated. After 
purification, the interactions between the protein-DNA complexes are reversed and the 
recovered DNA is further processed for sequence determination (Adapted from Mardis, 
2007).  
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biology. Besides the key transcription regulators including Oct4, Sox2 and Nanog, other 
novel regulators that may be critical for ES cell maintenance have not been extensively 
studied.  
 
Mouse ES cells depend on signaling pathways and transcription factors to maintain their 
undifferentiated state. The downstream effectors of these signaling pathways and 
transcription factors may be as candidate regulators of the self-renewal and pluripotency 
of ES cells. Transcription factor Nanog plays critical roles in undifferentiated ES cells 
with unknown mechanisms. This project aimed to decipher the function of Nanog in 
mouse ES cells through identifying its downstream effectors that are involved in 
maintaining the self-renewing and pluripotent state of ES cells. The finding from this 






















CHAPTER TWO  












Chapter II. Materials and Methods 
2.1. Cell culture  
Mouse E14 ES cells were cultured under a feeder-free condition at 37°C with 5% CO2. 
The cells were maintained on gelatin-coated dishes in Dulbecco’s modified Eagle 
medium (DMEM; GIBCO), supplemented with 15% heat-inactivated fetal bovine serum 
(FBS; GIBCO), 0.055 mM β-mercaptoethanol (GIBCO), 2 mM L-glutamine, 0.1 mM 
MEM nonessential amino acid, 5,000 units/ml penicillin/streptomycin and 1,000 units/ml 
of LIF (Chemicon). 293T cells were cultured in Dulbecco’s modified Eagle’s medium 
(GIBCO) supplemented with 10% heat-inactivated fetal bovine serum (GIBCO) and 
maintained at 37°C with 5% CO2. 
 
2.2. Knockdown and overexpression plasmids and cell transfection  
19 base pair (bp) gene-specific oligonucleotides for RNA interference (RNAi) were 
designed with the criteria defined by the work of Reynolds et al. (2004) and Ui-Tei et al. 
(2004). The RNAi oligonucleotides were cloned into pSuperpuro (Oligoengine) with 
BglII and HindIII sites which carries a puromycin resistant gene driven by a PGK 
promoter, and 19-bp short hairpin RNAs (shRNAs) with a 9-bp loop were expressed by 
the pSuperpuro plasmids. To ensure the specificity of the oligonucleotides for RNAi, all 
sequences were analyzed by BLAST search to remove any cross effect with other genes. 
For rescue experiments, RNAi constructs were co-transfected with a construct expressing 
mutated ORF of the targeting gene through which the target site of shRNA sequence was 




Transfection of shRNA and overexpression plasmids was performed using Lipofectamine 
2000 (Invitrogen). For RNA and protein extraction, 2 μg of shRNA or overexpression 
plasmids were transfected into ES cells on 60mm plates. For RNAi ChIP assay, 18 μg of 
shRNA plasmids were transfected into ES cells on 15cm plates. Puromycin (Sigma) 
selection at 1.0 µg/ml was introduced 24 hours after transfection, and maintained for 2-6 
days prior to harvesting. Alkaline phosphatase staining was carried out using a 
commercial ES Cell Characterization Kit from Chemicon. For the overexpression 
plasmid, Nanog ORF was cloned into pCAGpuro or pCAGhygro tagged by 3XFlag. To 
establish the Nanog overexpression cell lines, 2 μg of pCAGpuro or pCAGhygro inserted 
with Nanog ORF were transfected into ES cells on 60mm plates. After one-week 
selection with puromycin (1ug/ml) or hygromycin (300ug/ml), 10 colonies were picked. 
By using western blot, the expression level of Nanog was checked which was detected by 
the antibodies against Flag and Nanog. Empty pCAGpuro or pCAGhygro was used as a 
control.  
 
2.3. Luciferase reporter assay 
For Nanog-luc, a 5.5kb fragment of the mouse Nanog promoter was cloned into pGL3-
Basic plasmid (BglII and NcoI sites) upstream of the firefly luciferase gene (Promega). 
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To study the effects of knockdown on the Nanog promoter, 100 ng of mouse Nanog-luc 
plasmid, 100 ng of shRNA plasmid (pSuperpuro; Oligoengine), and 5 ng of plasmid 
containing Renilla luciferase (pRL-SV40; Promega) were co-transfected into E14 cells. 
The pRL-SV40 plasmid was used as a control for normalizing the transfection efficiency. 
Firefly and Renilla luciferase activities were measured 48 hours after transfection by 
using the Dual Luciferase System (Promega) and a Centro LB960 96-well luminometer 
(Berthold Technologies). 
 
2.4. RNA isolation, reverse transcription and real-time PCR analysis 
The total RNA of cells was extracted by using Trizol reagent (Invitrogen) and further 
purified with the RNeasy minikit (Qiagen). 500ng of the total RNA purified were used 
for cDNA synthesis by the SuperScript II kit (Invitrogen). 2 μl of the reverse 
transcription reaction product was mixed with 5μl SYBR Green mix reagent (Applied 
Biosystems), 50 nM forward primers and 50 nM reverse primers in a 10 ul reaction 
system. And the mixture was further loaded to the ABI Prism 7900HT machine (Applied 
Biosystems) for the measurement of the endogenous mRNA levels. Each sample was 
performed in duplicate. Results were normalized with β-actin. For all the primers used, 
each gave a single product of the right size. 
 
2.5. Protein extraction and western blotting 
Total protein extracts were extracted by lysing cells with the whole cell extraction buffer 
(Tris, 50mM; Nacl, 150mM; NP40, 1%; Glycerol, 10%; EDTA, 1mM; PMSF, 1mM). 
30μg of the total protein were separated by SDS–PAGE and transferred to PVDF 
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membrane. The membrane was blocked with 5% milk and probed with specific primary 
antibodies and secondary antibodies. The blots were developed with ECL Advance 
Western Blotting Detection Kit (Amersham). Rabbit anti-mouse Nanog antibody and 
anti-mouse Esrrb antibody were produced by our lab; F-3165 mouse anti-Flag antibody 
and mouse monoclonal anti-ß actin antibody were from Sigma. 
2.6. Microarray 
For Nanog-depleted ES cells, Nanog-overexpressed ES cells and RA-treated Nanog 
overexpressers, Affymetrix Mouse Genome 430 2.0 Array arrays were used to profile the 
gene expression. Three biological repeats were performed for each of these experimental 
groups. The probes for hybridization were prepared by GeneChip One-Cycle Target 
Labeling kit (Affymetrix). The microarray data files are deposited at GEO database. 
RMA (Robust Multichip Averaging) method was employed to normalize the array data. 
After the normalization I used Significance Analysis of Microarray (SAM) statistics to 
select differentially expressed genes from the two groups. SAM (http://www-
stat.stanford.edu/~tibs/SAM) uses permutations of the repeated measurements to estimate 
the percentage of genes identified by chance. The selected genes have a median FDR 
(false discovery rate) of less than 0.001.  
 
For the Esrrb-depleted ES cells, Illumina microarray platform (Sentrix Mouse-6 
Expression BeadChip v 1.0) was used. The mRNAs derived from Esrrb shRNA 1 and 
Gfp shRNA treated ES cells were reverse transcribed, labeled and analyzed using. Arrays 
were processed following the manufacturer’s instructions. Three biological replicates of 
the profiles were performed for Esrrb-depleted ES cells and Gfp knockdown control.  
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Rank Invariant normalization was use to normalize the microarrays. Significance analysis 
of microarrays (SAM) was used to select differentially expressed genes.  The 
differentially expressed genes were selected based on the following three criteria (Fold 
change (FC)>1.5 for up-regulated, FC<0.6 for down-regulated; q value<2%; and 
detection probability greater than 0.99 in all samples.   
2.7. ChIP assay 
ES cells were cross-linked with 1% (w/v) formaldehyde for 10 min at room temperature 
and formaldehyde was then inactivated by the addition of 125 mM glycine. Chromatin 
extracts containing DNA fragments with an average size of 500 bp were 
immunoprecipitated using anti-Oct4 (sc-8628, Santa Cruz), anti-Nanog (Cosmo Bio), 
anti-Esrrb (amino-acids 1 to 200 of mouse Esrrb raised in rabbit) or anti-GFP (sc-9996, 
Santa Cruz) antibodies. Quantitative PCR analyses were performed in real-time using the 
ABI PRISM 7900 sequence detection system and SYBR green master mix. Threshold 
cycles (Ct) were determined for both immunoprecipitated DNA and known amount of 
DNA from input sample for different primer pairs. Relative occupancy values (also 
known as fold enrichments) were calculated by determining the IP efficiency (ratios of 
the amount of immunoprecipitated DNA to that of the input sample) and normalized to 
the level observed at a control region, which was downstream of Nanog gene 
(chr6:123352993-123353158) (mm5 genome build) and defined as 1.0. For all the 
primers used, each gave a single product of the right size, as confirmed by agarose gel 
electrophoresis and dissociation curve analysis.  
 
2.8. Electrophoretic mobility shift assay (EMSA) 
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The EMSA double-stranded probes (Proligo) were prepared through annealing the sense 
oligonucleotide strands labeled with biotin at the 5_ termini with the reverse strands in 
the annealing buffer (10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM EDTA). The 
annealed probes were purified by using an agarose gel DNA extraction kit (QIAGEN). 
1ng of purified probes were mixed with 1ug of polydG/dC (Amersham), 2ul of 5x 
reaction buffer (10mM HEPES, pH7.5, 10mM KCl, 10mM MgCl2, 1mM DTT, 1 mM 
EDTA, 10% glycerol), and 120ng of Nanog homeodomain, full-length Oct4 or full-length 
Esrrb protein which were purified by using GSH-sepharose beads (Amersham) and 
dialyzed at 4oC overnight with the dialysis buffer (20mM HEPES, pH7.9, 20% glycerol, 
100mM KCl, 0.83mM EDTA, 1.66mM DTT). The concentration of the protein was 
measured with a Bradford assay kit (Bio-Rad). The reaction mixtures were incubated at 
room temperature for 20 minutes. The different complexes in the reaction mixtures were 
separated by electrophoresis by using 10% DNA PAGE gels which had pre-run for 1 
hour at 4oC. The gels were transferred to Biodyne B nylon membranes (Pierce 
Biotechnologies) and detected using the LightShift Chemiluminescent EMSA kit (Pierce 
Biotechnologies). 
 
2.9. Esrrb ChIP sequencing library construction and data processing  
10 ng of Esrrb ChIP DNA and GFP ChIP control DNA fragments prepared were 
processed for cluster generation and sequencing on the Illunima cluster station and 1G 
analyzer by using the methods described in the previous study by Robertson et al. (2007). 
The sequencing reads were extracted and mapped to the mouse genome (mm8) 
(Chromosome1-22 and X) through the Eland application (Illunima). No more than 2 
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mismatches per 26bp read sequence were permitted and only uniquely mapped read 
sequences were retained for further analysis. The mapped reads were then transformed 
into the profiles of overlapped numbers at each reference genome position, which was 
performed according to the method in the previous study (Robertson et al., 2007). The 
putative binding peaks chosen located where the maximal numbers of ChIP fragments 
resided within a ±500 bps interval were found. To determine a peak height, FDR (false 
discovery rate) was calculated which is the ratio of the number of non-specific peaks 
which should occur randomly indicated by a background model to the number of real 
peaks observed. By using Monte Carlo simulation, the smallest peak height of 
(FDR<0.05) was chosen to be as a cutoff threshold. Through comparing the peak heights 
of Esrrb ChIP-sequencing library with the peak heights of the negative control GFP 
ChIP-sequencing library at the same locations, the non-specific peaks were further 
filtered out and the peaks with a height ≥ 5 fold were kept and defined as transcription 

































Chapter III. Results 
3.1. The roles of Nanog in mouse ES cells 
Nanog has been regarded as a key transcription factor involved in the maintenance of ES 
cells and the processes of embryogenesis (Chambers et al., 2003; Mitsui et al., 2003). 
The instrumental roles of Nanog in ES cells have attracted great interests to uncover the 
mechanisms underlying its functions. This project sought to identify the downstream 
targets of Nanog which could be important for maintaining the undifferentiated state of 
ES cells. To achieve that, I had undertaken a combinatorial approach of gene expression 
profiling upon the genetic manipulations of Nanog with chromatin immunoprecipitation 
(ChIP) assay.  
 
3.1.1. Nanog knockdown led to mouse ES cell differentiation 
I speculated that if a gene is functionally targeted by Nanog, its expression should be 
alerted along with the perturbation of Nanog expression. To knockdown Nanog in ES 
cells, short-hairpin RNA interference (shRNAi) technology was employed. The Nanog 
shRNA construct was effective in reducing the mRNA and protein levels of Nanog 
(Figure 3.1A). Consistent with previous reports, Nanog depletion resulted in flattened 
fibroblast-like morphology and the differentiated cells lost the red staining signal of 
alkaline phosphatase (Figure 3.1B) (Chambers et al., 2003; Mitsui et al., 2003). As would 
be expected with the distinct differentiation morphology, the expression levels of 
pluripotent markers, Oct4, Sox2 and Rex1, were significantly decreased, while multiple 
lineage markers were induced (Figure 3.1C and D). Notably, endoderm markers, Sox17 
and Gata4 were up-regulated in the Nanog-knockdown ES cells. This is supported by the 
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phenotype of Nanog-null embryos which are deficient in the formation of primitive 
ectoderm (Mitsui et al., 2003). Nanog knockdown also induced the expression of 
trophectoderm marker genes (Hand1 and Cdx2), mesendoderm marker (Msx1) and 
mesoderm gene (Brachyury). Hence, the resulting cells were likely to be composed of 
multiple differentiated cell types. Taking into consideration of the cellular differentiation 
morphology, the expression reduction in pluripotency markers and induction of lineage 
markers, the results have shown that Nanog plays an important role in maintaining the 
undifferentiated state of ES cells.  
 
To substantiate the specificity of the Nanog shRNA construct, a rescue experiment was 
performed by using the RNAi-immune Nanog cDNA expression plasmid. This plasmid 
contains two synonymous amino-acid substitutions at the shRNA targeting site (Figure 
3.2A). The Nanog shRNA construct was co-transfected along with the RNAi-immune 
Nanog cDNA expression plasmid. As compared to the vector control, the RNAi-immune 
Nanog rescued the differentiation of ES cells that was induced by knockdown of 
endogenous Nanog (Figure 3.2A). In addition, endogenous Nanog was effectively 
depleted in the cells with co-tranfection of Nanog shRNA and control overexpression 
vector, while exogenous Nanog was expressed from the RNAi-immune construct in the 
cells co-transfected with either the Gfp shRNA or the Nanog shRNA (Figure 3.2B). To 
further demonstrate the rescue effect, I measured the expression levels of various ES cell-
associated genes. Oct4 mRNA level which was down-regulated to 50% by Nanog 
knockdown was restored to 80% in the Nanog rescue cells (Figure 3.2C). The induction 
of Gata6 expression was reversed to almost the same level with the Gfp shRNA-
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transfected control cells (Figure 3.2C). Together, these results verified the specificity of 





















































































































































Figure 3.1 shRNA-mediated Nanog knockdown led to ES cell differentiation. A. The 
Nanog shRNA construct was effective in reducing Nanog at both mRNA (upper 
panel) and protein level (lower panel). Nanog mRNA level relative to the Gfp shRNA-
transfected control cells was determined by reverse transcription followed by real-time 
PCR. Data are presented as the mean ± SEM. Nanog protein level was detected by 
western blotting and the lysates were probed using anti-Nanog or anti-ß actin 
antibodies. Both RNA and cell lysates were harvested after 4 days of puromycin 
selection. B. Flattened fibroblast-like cells were formed after Nanog knockdown and 
the cells lost the red staining signal of alkaline phosphatase, while alkaline 
phosphatase-positive ES cell colonies were maintained in the Gfp shRNA-transfected 
control cells. The cells were stained after 4 days of puromycin selection. C. 
Expression profiles of pluripotent markers after Nanog knockdown. The mRNA levels 
relative to the Gfp shRNA-transfected control cells were analyzed after 4 days of 
puromycin selection. Data are presented as the mean ± SEM. D. Real-time PCR 
showing the expression level changes of various lineage-specific markers in Nanog-
depleted ES cells. The mRNA levels were analyzed after 4 days of puromycin 
selection and normalized against control the Gfp shRNA-transfected cells. Data are 

























































































Gfp shRNA + Vector Gfp shRNA + Nanog Mut 
Nanog shRNA + Vector Nanog shRNA + Nanog Mut 
Nanog shRNA target  
Nanog Mut
Amino Acid
GAG AAC TAT TCT TGC TTA CAA 
GAG AAT TAT AGC TGC CTA CAG 





3.1.2. Establishment of Nanog overexpression ES cell line 
To further characterize the roles of Nanog in ES cells, its expression level was elevated 
by using the episomal expression system (Gassmann et al., 1995; Chambers et al., 2003; 
Mitsui et al., 2003). In this system, two constructs, pMGD20neo and pCAGIpuro were 
introduced into mammalian cells (Figure 3.3A) (Gassmann et al., 1995; Chambers et al., 
2003). The pMGD20neo construct contains a modified polyoma early region encoding 
the large tumor (Py large T) antigen, which can activate the polyoma origin (ori) 
contained in the pCAGIpuro construct. This serves to support the episomal replication of 
pCAGIpuro in the mammalian cells and prevents its integration into the chromosomes. 
Because of its high transfection efficiency (>90%) and stability, this episomal expression 
system is also known as the “super transfection system”.  
 
To establish the Nanog overexpression stable cell line, I performed two rounds of 
transfection. Firstly, the pMGDneo construct was transfected into ES cells. After five 
Figure 3.2 The rescue experiment demonstrating the specificity of the Nanog shRNA 
construct. A. The expression of RNAi-immune Nanog cDNA rescued Nanog shRNA-
induced cell differentiation.  Silent mutations were introduced into the Nanog open 
reading frame (ORF). The mutated region was no longer fully complementary to the 
shRNA, which rendered the transcript resistant to RNAi. This RNAi-immune Nanog 
expression plasmid was co-transfected along with the Nanog shRNA construct. Gfp 
shRNA construct and the rescue vector without Nanog cDNA insertion were used as 
controls.  The pictures were taken 3 days after transfection. The lower panel shows the 
Nanog shRNA target sequence (in blue highlight) and the residues with silent 
mutations (in red). B. Endogenous Nanog was effectively depleted while exogenous 
Nanog was equally overexpressed in the Gfp shRNA- and the Nanog shRNA-
transfected cells. The expression levels of Nanog were detected by reverse 
transcription followed by real-time PCR. Data are presented as the mean ± SEM. C. 
The expression of RNAi-immune Nanog cDNA rescued the effect of Nanog RNAi on 
the expression of both pluripotent gene Oct4 (left panel) and lineage marker Gata6 
(right panel). Data are presented as the mean ± SEM.  
 57
days of neomycin selection (350ng/ul), 20 clones were picked and screened for their 
expression of large T gene by qPCR detection (data not shown). The clone with the 
highest large T expression was selected and subjected to a second round of transfection 
with the pCAGIpuro construct that expresses the Nanog cDNA. After 4 days of selection 
with both neomycin (350ng/ul) and puromycin (1ng/ul), 10 clones were picked and 
further checked for Nanog expression via western blotting (data not shown).  Based on 
the criterion of high Nanog expression level, Clone F4 was selected and used for 
subsequent experiments. Transfection with mock pCAGIpuro vector was also performed 
to generate clone CAG to serve as a negative control. Western blot analysis showed that 
the expression level of Nanog in clone F4 was approximately eight times higher than the 
control cell line (Figure 3.3B). I next tested the ability of the Nanog-overexpressed cell 
line F4 in resisting differentiation. LIF was withdrawn from the ES culturing medium, 
which led to complete differentiation of the control CAG cells. However, the Nanog-
overexpressed cell line F4 retained the colony morphology of ES cells (Figure 3.3C). 
Consistent with previous findings of Chambers et al. (2003), this result indicates that 
Nanog overexpression conferred the LIF independence of mouse ES cells. To check if the 
Nanog-overexpressed cells can also resist RA-induced differentiation, the cells were 
treated with 0.3μM of RA for 48 hours. While undifferentiated cells could hardly be 
found in the control CAG cells, the Nanog-overexpressed cell line F4 exhibited limited 
differentiation and retained the ES cell phenotype (Figure 3.3D). These experiments 
validated that the F4 cell line expressed a high level of exogenous Nanog that is 
functionally active. I subsequently used the F4 clone for further studies to dissect the 
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3.2. Estrogen related receptor beta (Esrrb) is a novel target of Nanog 
To identify novel targets acting downstream of Nanog, affymetrix microarrays were used 
for expression profiling of mouse ES cells that were subjected to Nanog knockdown or 
Nanog overexpression (Figure 3.4). As compared to the Gfp shRNA knockdown control, 
855 genes were down-regulated upon Nanog depletion (Figure 3.5A). On the other hand, 
the profiling of the clone F4 cells showed that 215 genes were up-regulated (Figure 3.5A). 
Among the responsive genes, 32 genes were positively regulated by Nanog as their 
expression levels were elevated in the clone F4 cells and reduced in Nanog-depleted ES 
cells (Figure 3.5A) (Appendix 1). These 32 genes are enriched for transcription factors 
that could potentially have critical roles in regulating the expression program specific to 
the ES cell state. I next asked if Nanog could maintain the expression levels of its 
prospective targets under differentiation-induced condition. To this end, I performed 
genome-wide expression profiling of the RA-treated F4 cell line. Following the RA 
treatment, the expression levels of 513 genes were sustained under the condition of 
Nanog-overexpression (Figure 3.5B). 15 genes were identified to be positively regulated 
Figure 3.3 Establishment and characterization of Nanog-overexpressed cell line F4. 
A. The constructs used for establishing the Nanog overexpression ES cell line. B. 
Nanog was substantially overexpressed in the clone F4 cells. Cell lysates of the clone 
F4 cells and clone CAG control cells were analyzed by western blot using anti-Nanog 
and anti-ß actin antibodies. The higher molecular weight of overexpressed Nanog was 
due to the presence of an epitope-tag. The band representing endogenous Nanog was 
indicated. C. Nanog overexpression conferred ES cells resistance to LIF withdrawal. 
Nanog-overexpressed ES cells (Clone F4) and control ES cells (Clone CAG) were 
grown in the presence of LIF (+LIF) or absence of LIF (-LIF) for 60 hours. D. Nanog 
overexpression rendered ES cells resistant to RA-induced differentiation. Nanog-
overexpressed ES cells (Clone F4) and control ES cells (Clone CAG) were grown in 
the presence 0.3 μM RA (+RA) or no RA (-RA) for 48 hours. 
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by Nanog and sustained in the RA-treated F4 cells (Figure 3.5B and C). I noticed that 
Oct4 and Sox2 were not upregulated upon Nanog overexpression even though 
overexpressed Nanog maintained Oct4 under the RA-treated condition (data not shown). 
Figure 3.4 provides an illustrative model by which Nanog regulates these 15 genes. In 
self-renewing ES cells, the activity of Nanog target genes is positively regulated by 
Nanog. Overexpression of Nanog elevates the expression of these genes, while 
knockdown of Nanog results in suppression of their expression. Under a differentiation-





















Since the focus of this project is on transcription factors, 3 genes out of the 15 genes were 
short-listed due to their potential roles in transcriptional regulation. These three genes 
include Estrogen related receptor beta (Esrrb), amino-terminal enhancer of split 
(Esp1/Grg5/Aes) and BTB (POZ) domain containing 1 (Btbd1) (Pettersson, et al., 1996; 
Xie et al., 1999; Lu et al., 2001; Sanyal et al., 2002; Brantjes et al., 2001). Among the 
three candidate genes, only Esrrb has been reported to be closely related with pluripotent 
cells (Pettersson, et al., 1996). Pluripotent EC cells and ES cells have an elevated 
expression of Esrrb, and this elevated expression disappears upon differentiation 
(Pettersson, et al., 1996). This implies that Esrrb may be involved in maintaining 
pluripotent ES cells. To further confirm the regulatory effect of Nanog on Esrrb, I 
performed reverse transcription assay followed by realtime PCR to confirm the 
microarray results. In Nanog-knockdown ES cells, Esrrb expression level was reduced to 
about 30% (Figure 3.5D). Conversely, Esrrb transcript level was enhanced by 2 folds in 
the clone F4 cells in comparison with the clone CAG cells. This induction by Nanog 
could explain the maintenance of Esrrb level in RA-treated F4 cell line (Figure 3.5E). In 
addition, I found that in the Oct4-depleted ES cells, Esrrb was also dramatically down-
regulated to about 20% (Figure 3.5D). All these findings suggest that the expression of 
Esrrb is closely associated with the pluripotent state of ES cells. 
Figure 3.4 Schematic diagram illustrating the strategies undertaken to identify novel 
regulators of ES cells. The total RNA from the Nanog-depleted ES cells, Nanog-
overexpressed F4 cell line and RA-treated F4 cell line were extracted and analyzed by 
Affymetrix GeneChip expression microarray. Downstream effector “A” which is 
positively regulated by Nanog is a candidate for novel regulators that maintain the 
“stemness” state of the ES cells. The transcript unit of “A” is depicted as a white box. 























Nanog overexpression Nanog RNAi 
Nanog overexpression 
















































































Figure 3.5 Esrrb is a downstream target positively regulated by Nanog. A. Venn 
diagram showing overlaps of the genes that were up-regulated in Nanog-
overexpressed F4 cell line and down-regulated in Nanog-depleted ES cells. B.Venn 
diagram showing overlaps of the genes which were up-regulated in Nanog-
overexpressed F4 cell line, down-regulated in Nanog-depleted ES cells, and 
maintained in the F4 cell line treated with RA. C. Heatmap showing the expression 
profile of the 15 genes which are positively regulated by Nanog. The genes were 
selected based on the fold changes of their expression levels after Nanog depletion and 
overexpression. They were sorted by the average expression ratio and mean centered. 
Five replicates were used for the Nanog depletion experiment while triplicates were 
used for the Nanog overexpression experiment. D. Realtime PCR validation for Esrrb 
level in Nanog- and Oct4-depleted ES cells. Data are presented as the mean ± SEM. E. 
Realtime PCR validation for Esrrb level in Nanog overexpression F4 cell line (Left 
panel) and upon RA-induced differentiation (Right panel). Data are presented as the 
mean ± SEM. 
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To validate the direct regulation of Esrrb by Nanog, others in our lab have performed 
chromatin immunoprecipitation (ChIP)-paired end ditag (PET) mapping and identified 3 
intronic regions in the Esrrb locus where Nanog is bound (Loh et al., 2006) (Figure 3.6A). 
I confirmed the binding of Nanog by means of ChIP-quantitative PCR (qPCR) (Figure 
3.6B). Moreover, I validated the Oct4 binding to the Esrrb intronic regions by ChIP-
qPCR (Loh et al., 2006) (Figure 3.6 B). By means of electrophoretic mobility shift assay 
(EMSA), I showed that Nanog and Oct4 directly interact with the Esrrb genomic DNA 
fragments containing either the Nanog or Oct4 binding motif (Figure 3.6C and D). 
Importantly, the interactions were abolished upon the introduction of mutations in the 
Nanog or Oct4 binding motif. These findings suggest that Esrrb is bound and positively 



















































































1 2 3 
WT  GATCCCAGTCTTTCAGATGCAAAAATAGCTGATTGCACTG 
Mut  GATCCCAGTCTTTCAGCCCCAAAAATAGCTGATTGCACTG 
Free probe 
Figure 3.6 Nanog and Oct4 bind to Esrrb in vivo and in vitro. A. ChIP-PET mapping 
shows that Esrrb is bound by Nanog (red blocks N1-3) and Oct4 (blue blocks O1-2). 
Exons are depicted as gray boxes. The arrow indicates the direction and body of Esrrb 
gene, extending from first exon to last exon based on the University of California, Santa 
Cruz mouse genome coordinates. The numbers on the right indicate the window span 
represented. B. ChIP assay using Nanog antibody (left panel) and Oct4 antibody (right 
panel) confirmed their binding to the Esrrb locus. Data are presented as the mean ± 
SEM. C. In vitro binding of Nanog to the intronic sequences of Esrrb. EMSA was used 
to analyze the interaction between Nanog and a double-stranded DNA probe (WT) 
containing a Nanog binding motif labeled in red in the bottom panel (Loh et al., 2006). 
The N3 Nanog binding site with the highest enrichment was selected for probe design 
and purified Nanog homeodomain was used for the assay. As compared to the control 
(No purified protein was added to the interaction mixture with probes) (Lane1), Nanog 
homeodomain formed a Nanog/DNA complex with the probe used (Lane2). Mutations 
introduced to the probe (Mut, mutated motif labeled in blue) dramatically suppressed its 
interaction with the Nanog homeodomain (Lane3). D. Oct4 binds to the intronic 
sequences of Esrrb. EMSA was used to analyze the interaction between Oct4 and a 
double-stranded DNA probe (WT) containing an Oct4 binding motif labeled in red (Loh 
et al., 2006). The O1 Oct4 binding site with the highest enrichment was selected for 
probe design and purified Oct4 protein was used to detect the Oct4/DNA interaction. As 
compared to the control (No purified protein was added to the interaction mixture with 
probes) (Lane1), Oct4 formed a Oct4/DNA complex with the probe (Lane2). In contrast, 
the mutant probe (Mut, mutated motif labeled in blue) could not interact with the Oct4 
protein (Lane3).  
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3.3. Esrrb plays a role in maintaining undifferentiated ES cells 
To investigate the role of Esrrb in regulating ES cells, its expression was depleted using 
two shRNA constructs that target different sites of the Esrrb mRNA. Both constructs 
efficiently reduced the mRNA level of endogenous Esrrb (Figure 3.7A). More strikingly, 
Esrrb knockdown using the shRNA constructs resulted in ES cell differentiation (Figure 
3.7B). The knockdown cells could not grow as colonies and became fibroblast-like. 
Moreover, alkaline phosphatase staining showed that Esrrb-depleted cells lost the 
characteristic red staining signal (Figure 3.7B). I further measured the expression levels 
of different marker genes, and found that the cellular differentiation induced by Esrrb 
knockdown was accompanied by a corresponding reduction in pluripotency markers and 
induction of genes associated with differentiation (Figure 3.7C and D). The Nanog and 
Rex1 expression were decreased by 50% and 40% respectively. The Oct4 and Sox2 
expressions were reduced subtly. Developmental marker genes, Msx1, Fgf5, Hand1 and 
Cdx2, were induced significantly. However, two endoderm markers, Sox17 and Gata4, 
were reduced by Esrrb depletion. These results indicate that Esrrb-depleted ES cells are 






































































To demonstrate the specificity of the Esrrb shRNA constructs, two control experiments 
were performed. Firstly, the Esrrb shRNA sequences were scrambled. Both of the 
scrambled Esrrb shRNA constructs did not lead to cellular differentiation (Figure 3.8A 
















































































Figure 3.7 shRNA-mediated knockdown of Esrrb led to ES cell differentiation. A. 
Esrrb was effectively depleted by both of the two shRNA constructs that target 
different regions of Esrrb. The mRNA levels of Esrrb were determined by real-time 
PCR quantification of reverse-transcribed RNAs after 4 days of puromycin selection. 
Data are presented as the mean ± SEM. B. Esrrb-depleted ES cells underwent 
morphological differentiation. Positive alkaline phosphatase staining was used to 
define undifferentiated cells. As compared to the Gfp shRNA-mediated knockdown 
control, flattened fibroblast-like cells were formed after Esrrb knockdown and the red 
alkaline phosphatase-staining signal was lost. Two Esrrb shRNA constructs were used 
to show RNAi specificity. The cells were stained after 4 days of puromycin selection. 
C. Real-time PCR analysis of ES cell-associated gene expressions in the Esrrb-
depleted ES cells. Cells were harvested after 4 days of puromycin selection. The levels 
of the transcripts were normalized against the Gfp shRNA-transfected cells. Data are 
presented as the mean ± SEM. D. Real-time PCR analysis of lineage-specific marker 
gene expressions in the Esrrb-depleted ES cells. Cells were harvested after 4 days of 
puromycin selection. The levels of the transcripts were normalized against the Gfp 
shRNA-transfected cells. Data are presented as the mean ± SEM.  
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(Figure 3.8C). In addition, the down-regulation of Nanog by Esrrb knockdown was 
restored, while the induction of Fgf5 after Esrrb knockdown was not observed in the 
scrambled shRNA-transfected cells (Figure 3.8C).  Next, the rescue experiment was 
performed by using the RNAi-immune Esrrb cDNA expression plasmid with two 
synonymous substitutions at the RNAi target sites. I co-transfected the plasmid 
containing either the wild-type Esrrb ORF or Esrrb shRNA1-immune cDNA along with 
Esrrb shRNA constructs into 293T cells. Figure 3.9A shows that both shRNA1 and 
shRNA2 abolished the expression of the Esrrb protein from the wild-type ORF. However, 
only shRNA2 was effective in down-regulating the protein level of Esrrb from the Esrrb 
shRNA1-immune cDNA (Figure 3.9A). A similar result was observed when the 293T 
cells were transfected with the Esrrb shRNA2-immune cDNA (data not shown). These 
results demonstrated the feasibility of using the RNAi-immune cDNAs to rescue the 
effects of knockdown induced by shRNAs. The Esrrb shRNA constructs were next co-
transfected along with the RNAi-immune Esrrb cDNA expression plasmid into ES cells. 
Expectedly, the RNAi-immune Esrrb could rescue the cellular differentiation induced by 
knockdown of endogenous Esrrb (Figure 3.9B). Like the scrambled shRNA experiment, 
the knockdown effects of Esrrb on Nanog and Fgf5 expression were rescued by the 
shRNA-immune Esrrb cDNA construct (Figure 3.9C). Taken together, the Esrrb shRNA 
constructs are specific in depleting the intended targets and the cellular differentiation 
induced by the shRNA-mediated Esrrb knockdown is not due to aberrant off-targeting 
effects. On the other hand, Esrrb-overexpressed ES cells maintained the morphology 







Esrrb scrambled 1S: GAAGGCAGUUUAUUCAGUA 
Esrrb scrambled 2S: GCCCUACCUGAAAUGUUAU
Esrrb shRNA 1:          GAUUCGAUGUACAUUGAGA 







































































































Figure 3.8 Scrambled Esrrb 
shRNAs did not lead to ES 
cell differentiation. A. ES 
cells expressing scrambled 
Esrrb shRNA sequences 
retained undifferentiated cell 
morphology. B. Sequences of 
Esrrb shRNAs and scrambled 
shRNAs. C. The scrambled 
shRNAs rescued the Esrrb 
knockdown effects on Esrrb, 
Nanog and Fgf5 levels. The 
levels of the transcripts were 
normalized against the Gfp 
shRNA-transfected cells. Data 
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Esrrb shRNA2 target     
shRNA1-immune ORF 
Amino Acid
Esrrb shRNA1 target     
shRNA1-immune ORF 
Amino Acid
AAG ATC GTC TCG AAT CTA CTA 
AAG ATT GTT TCT AAC CTG CTC 
   K   I   V   S   N   L   L 
 
GAT TCG ATG TAC ATT GAG AAC 
GAC TCC ATG TAT ATC GAA AAC 




















3.4. Genome-wide mapping of Esrrb targets in ES cells 
Since Esrrb is a transcription factor, it could exert its functions in ES cells by regulating 
the expressions of genes. As such, I sought to identify the targets of Esrrb in ES cells by 
using the newly developed ChIP-sequencing technology (Solexa, Illumina Inc). 
 
3.4.1. Generation of Esrrb antibody for ChIP-sequencing assay  
To identify the genomic locations of Esrrb binding, antibodies against Esrrb were 
generated. For the generation of antigens, I first performed Blast analysis and identified a 
region (aa 1-200) specific to Esrrb. The cDNA that encodes this fragment was cloned into 
the PET42b (+) vector which contains a GST tag. The expressed recombinant Esrrb 
protein was purified using GSH-sepharose beads. Protein SDS-PAGE electrophoresis 
followed by Commassie blue staining showed that only one specific band with the correct 
Figure 3.9 Rescue experiment demonstrating the specificity of the Esrrb shRNA 
constructs. A. Specificity of the Esrrb shRNA constructs was tested by co-transfection of 
the vector inserted with Esrrb ORF or the Esrrb shRNA1-immune ORF with Esrrb 
shRNA 1 or Esrrb shRNA 2 into 293T cells. The cell lysates were analyzed by western 
blot with anti-HA tag. ß tubulin served as a loading control. The red arrows indicate the 
HA-tagged Esrrb. B. Silent mutations were introduced into the Esrrb ORF. The mutated 
regions were no longer fully complementary to the shRNAs, which rendered the 
transcript resistant to RNAi. This RNAi-immune Esrrb expression plasmid was co-
transfected along with the Esrrb shRNA constructs. Gfp shRNA construct and the vector 
without Esrrb cDNA insertion were used as controls.  The pictures were taken after 3 
days of selection. The lower panel shows the two Esrrb shRNA target sequences (in blue 
highlight) and the residues with silent mutations (in red). C. Esrrb shRNA-immune 
cDNA construct rescued the Esrrb knockdown effects on Nanog and Fgf5 levels. The 
levels of the transcripts were normalized against the Gfp shRNA-transfected cells. Data 
are presented as the mean ± SEM.  
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size was detected (Figure 3.10A). The purified proteins were then used to immunize 
rabbits for the production of polyclonal antibodies. 
 
To examine the specificity of the Esrrb antibody generated, western blotting was 
performed with lysates obtained from the Esrrb-overexpressed or Esrrb-depleted ES cells. 
A major band of the expected Esrrb size was detected in the control lysates (Mock OE 
and Gfp knockdown control). Notably, the intensity of this band was increased in the 
Esrrb-overexpressed ES cells. In contrast, the depletion of Esrrb mediated by both 
shRNA constructs abolished the signal (Figure 3.10B and C). These results demonstrate 

















Before embarking on the ChIP-sequencing assay, control experiments were performed to 
ensure that the antibody was able to specifically capture Esrrb-DNA interactions. 






























Figure 3.10 Generation and specificity of anti-Esrrb antibody for ChIP-sequencing. A. 
Commassie blue staining shows the recombinant Esrrb fragment (1-200aa) purified by 
using GSH-sepharose beads. 20mM GSH elution buffer was used to release protein 
from the beads, and the elution was collected into six 1.5ml-eppendoff tubes. 10ul from 
the six tubes of 1ml collections were loaded to SDS-PAGE protein gel for Commassie 
blue staining (Lane 1-6). B. Western blotting shows the induction of Esrrb protein level 
in Esrrb-overexpressed ES cells. The lysates were harvested 3 days after transfection 
and analyzed by with anti-Esrrb or anti-ß actin antibodies. C. Western blotting shows 
the depletion of Esrrb protein level in RNAi treated ES cells. The lysates were 
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Nanog (Wang, et al., 2006). Therefore, Esrrb may bind and regulate genes that are 
similarly regulated by Nanog in ES cells. To test the hypothesis, two Nanog target genes, 
Tcfcp2l1 and Rif1, were selected. For Tcfcp2l1, I scanned the 2.6kb promoter region and 
found regions of Esrrb binding (Figure 3.11A and B). The specificity of the Esrrb binding 
is demonstrated by the lack of fold enrichment when ChIP was performed on the Esrrb-
depleted ES cell chromatin (Figure 3.11C).  
 
Diethylstilbestrol (DES) is an Esrrb antagonist that inhibits its transcriptional activity 
(Tremblay et al., 2001). ES cells began to differentiate after three days of DES treatment 
(Figure 3.11D), presumably due to the prohibition of the Esrrb activity. The level of 
Esrrb mRNA remained constant throughout the three days of DES treatment, which 
suggests that DES functions by repressing the Esrrb activity at the protein level (Figure 
3.11E). This provided an alternative way to confirm the specificity of the Esrrb antibody 
to detect the Esrrb binding. Since the onset of differentiation was later than two days after 
DES treatment, I harvested the chromatin on the second day of the DES treatment for 
ChIP assay. As expected, the DES treatment suppressed the binding of Esrrb to the 
Tcfcp2l1 promoter (Figure 3.11F). For Rif1, I scanned its 760bp promoter sequence and 
identified regions with fold enrichment of Esrrb occupancy (Figure 3.12A and B). 
Similarly, the Esrrb knockdown and DES treatment reduced the enrichment of Esrrb 
binding to the Rif1 promoter (Figure 3.12C and D).  
 
It can thus be concluded that the antibody raised against Esrrb is well-suited for ChIP 
experiments with the aim of identifying the downstream target genes of Esrrb. Moreover, 
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the ChIP results from the Esrrb-depleted and DES-treated ES cell samples further 
highlighted the specificity of the Esrrb antibody. Having obtained these results, I 






























































































































Figure 3.11 Tcfcp2l1 is a target of Esrrb. A. Schematic diagram showing the location 
of the amplicons (black bars labeled 1-3) used to detect ChIP-enriched fragments over 
the 2.6 kb Tcfcp2l1 locus. Amplicons are numbered in order relative to their sites 
along the gene. The open box represents an exon. B. Real-time PCR detection of 
enriched fragments from the ChIP assay using Esrrb antibody. Fold enrichment is the 
relative abundance of DNA fragments at the amplified region over a control amplified 
region. GST antibody was used as a control. Data are presented as the mean ± SEM. 
C. Knockdown of Esrrb reduced the ChIP signal derived from anti-Esrrb antibody. ES 
cells were transfected with control Luc shRNA, Esrrb shRNA 1 or Esrrb shRNA 2. 
Primers for Tcfcp2l1 promoter region 1 were used. Data are presented as the mean ± 
SEM. D. DES treatment resulted in ES cell differentiation. ES cells were treated with 
10uM DES dissolved in 0.1% ethanol or control 0.1% ethanol for 3 days. 
Morphologies were examined by microscopy on each of the day. E. Expression level 
of Esrrb was maintained in DES-treated ES cells. ES cells were treated with control 
0.1% ethanol or 10uM DES for three days. RNA was harvested on each of the day. 
Data are presented as the mean ± SEM. F. Esrrb binding to the Tcfcp2l1 promoter 
region (region 1) was reduced upon DES treatment. ChIP assay was performed with 
the samples of ES cells treated with 10uM DES or control 0.1% ethanol for two days. 


















































Figure 3.12 Rif1 is a target of Esrrb. A. Schematic diagram showing the location of 
the amplicons (black bars labeled 1-4) used to detect ChIP-enriched fragments over the 
760 kb Rif1 promoter. Amplicons are numbered in order relative to their sites along the 
gene. The open box represents an exon. B. Real-time PCR detection of enriched 
fragments from ChIP assays in ES cells using anti-Esrrb antibody. Fold enrichment is 
the relative abundance of DNA fragments at the amplified region over a control 
amplified region. GST antibody was used as a mock ChIP control. Data are presented 
as the mean ± SEM. C. Knockdown of Esrrb abolished the ChIP signal derived from 
anti-Esrrb antibody. ES cells were transfected with control Luc shRNA, Esrrb shRNA 
1 or Esrrb shRNA 2. Primers for Rif1 promoter region 2 were used. Data are presented 
as the mean ± SEM. D. Esrrb binding to the Rif1 promoter region 2 was reduced upon 
DES treatment. ChIP assay was performed with the samples of ES cells treated with 







































3.4.2. Genome-wide mapping of Esrrb binding sites 
Figure 3.13 outlines the major procedural steps of the ChIP-sequencing technology. 
Esrrb-ChIP DNA fragments were generated for the Solexa sequencer. Mock GFP ChIP 
DNA sample was also generated to serve as a negative control. A total of 10,702,372 
sequencing reads were obtained for the Esrrb ChIP-sequencing library. After filtering out 
the noise obtained from the GFP-ChIP mapping, 7,937,535 sequencing reads were 
uniquely mapped to the mouse genome (mm8), among which 3,609,843 reads mapped to 
Chromosome1-22 and X were further processed for analysis. To define the specific 
binding sites of Esrrb, false discovery rate (FDR) analysis and normalization against a 
background peak generated in the GFP ChIP-sequencing library were performed. The 
clusters are defined as Esrrb binding sites only when they satisfy the criteria of 
FDR<0.05 and peak heights ≥ 5. As such, 76,384 clusters representing potential Esrrb 
binding were identified (www.t2g.bii.a-star.edu.sg.).  
 
To further confirm the mapping results, I randomly picked 100 enriched loci and 
performed Esrrb ChIP-qPCR.  Out of the 100 tested loci, 94 were validated as enriched 
sites for Esrrb (Appendix 3) (Figure 3.14 A and B). Incidentally, the remaining six loci 
contained low enrichment detected by the ChIP-sequencing technology and thereby 
assigned as false positives. In addition, loci with higher peak heights detected by the 
ChIP-sequencing technology had corresponding higher fold enrichment as detected by 
the ChIP-qPCR approach. This indicates a close correlation between the two assays used 
in the detection of the ChIP-enriched DNA fragments. Based on the validation results, I 
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set peak height of 13 as the cutoff for the ChIP-sequencing results to ensure a mapping 
accuracy of 100%. 17,548 Loci with peak height of 13 or higher were identified to be 
high confidence sites of Esrrb binding. To further establish the specificity of Esrrb 
binding, ChIP followed by quantitative PCR for the top 20 loci with the highest fold 
enrichment was performed by using the normal or Esrrb-depleted ES cell chromatin. 
Results showed that the Esrrb occupancies on all the tested loci were significantly 
reduced upon Esrrb knockdown (Figure 3.15). The loci of Rif1 and Tcfcp2l, which were 
previously identified as Esrrb targets from ChIP-qPCR assay, were also detected by the 
ChIP-sequencing (Solexa) method (Figure 3.16A and B). For Tcfcp2l1, ChIP-sequencing 





Figure 3.13 Workflow of ChIP-sequencing assay. The ChIP assay is processed to generate 
protein-DNA fragments by using the antibodies against Esrrb and GFP proteins. 
Oligonucleotide adapters are then linked to the small stretches of ChIP DNA to enable 
massively parallel sequencing. After size selection (150-300bp), all the resulting ChIP 
DNA fragments are sequenced simultaneously using the Genome Analyzer and Solexa 
sequencing technology. The resulting sequences are mapped back to the reference genome 
(mouse genome mm8), whereby the most frequently sequenced fragments formed peaks at 











Figure 3.14 ChIP-quantitative PCR (ChIP-qPCR) validation of Esrrb binding sites 
identified from the ChIP-sequencing dataset. A. Validation results for the loci with 
low and moderate peak heights for Esrrb ChIP (<30). The locus coordinates were 
labeled as number 1-47 (Appendix 3).  The first six loci show less than 2 folds of 
enrichment, suggesting that they are false positives. qPCR was performed with the 
Esrrb-ChIP DNA fragment, and the results were normalized against input DNA and a 
negative region without Esrrb binding. Data are presented as the mean ± SEM. B. 
Validation results for the loci with high peak heights (≥30). The locus coordinates 
were labeled as number 48-100 (Appendix 3). qPCR was performed with the Esrrb-
ChIP DNA fragment, and the results were normalized against input DNA and a 








Table 3.1 20 loci with high peak heights were chosen for validation by Esrrb ChIP-
quantitative PCR with the Esrrb-depleted ES cell chromatin. 
 

















































































































































































































































































Figure 3.15 Esrrb depletion led to the abolishment of Esrrb occupancy. The top 20 loci 
with the highest fold enrichments were selected from the 94 validated Esrrb-bound 
sites. Esrrb ChIP-qPCR was performed and the results were normalized against the 
input DNA and a negative region without Esrrb binding. Chromatin was harvested from 
ES cells transfected with Esrrb shRNA 1 after 4 days of selection. Gfp shRNA-


















Figure 3.16 The screen shot of the T2G browser showing the binding profiles of Esrrb 
on Tcfcp2l1 and Rif1 loci detected by ChIP-sequencing assay. A. Peaks corresponding 
to Esrrb binding at the locus of Rif1. A sharp peak at the Rif1 promoter as indicated by 
the red arrow was detected previously by ChIP-qPCR (Fig 3.12). B. Peaks 
corresponding to Esrrb binding at the locus of Tcfcp2l1. A sharp peak at the Tcfcp2l1 
promoter as indicated by the red arrow was detected previously by ChIP-qPCR (Fig 
3.11). Additionally, four novel peaks were detected in the intronic region of Tcfcp2l1 
by ChIP-sequencing. 
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Analysis of the dataset that contains the genome-wide bound sequences of Esrrb has 
generated a consensus cis element of Esrrb binding. Interesting, this element matched the 
enhancer element ERRE (estrogen related receptor element) that was previously 
described as the motif mediating Esrrb-DNA interaction (Figure 3.17) (See Discussion). I 
further performed an EMSA assay to confirm the in vitro binding activity of Esrrb to the 
consensus element. Five regions with high enrichment of Esrrb binding were randomly 
selected and the probes designed for these regions contain the ERRE motif. The EMSA 
results showed that all the five probes were shifted by recombinant Esrrb protein, and 
these interactions were abolished by the introduction of mutations to the probes in the 
ERRE motif (Figure 3.18). Based on these results, I concluded that Esrrb can interact 







Figure 3.17 The cis-element mediating Esrrb-DNA interaction identified from the 
Esrrb ChIP-sequencing dataset. This work was done by Han Xu from the 





Mut  CAAGTGAAAGTCAAGTGAAAGTCAAGTGAAGGTCAGGTCA 
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3.4.3. Distribution of Esrrb binding and gene expression profiling 
In order to characterize the targets of Esrrb, the binding clusters were mapped to 
annotated genes if they fall within 100kb upstream or downstream of a transcript unit 
(Figure 3.19A) (Wei et al., 2006; Loh et al., 2006). Binding sites within 10kb upstream 
or downstream of the nearest transcript units were defined as 5’proximal upstream and 
3’proximal downstream of genes respectively. The remaining binding sites outside the 
proximal regions and within the 100kb range were defined as 5’distal upstream or 
3’distal downstream of genes (Loh et al., 2006). Binding sites which are located further 
than 100kb away from the nearest genes were defined as gene desert regions.  
 
From the Esrrb ChIP-seq dataset, most of the Esrrb binding clusters (92.7%) could be 
annotated to known genes while only 1,285 binding sites (7.3%) were located in the gene 
desert regions (Figure 3.19B). Among the binding sites annotated to known genes, 6,371 
Esrrb binding clusters (36.3%) were located in the introns of transcript units, whereas 
only 1,421 binding sites (8.1%) were found in exonic regions. 2,286 (13%) and 2,579 
(14.7%) binding sites were located respectively in the 5’ proximal and distal upstream 
Figure 3.18 Esrrb can directly interact with double-stranded DNA sequences that 
contain the Esrrb binding motif. EMSA was performed to detect the interaction 
between purified Esrrb proteins and the respective DNA probes. Five regions (upper 
pannels in A-E) with high peak heights of Esrrb occupancy were chosen for probe 
design. The upper panels in A-E are the screen shots of the T2G browser showing the 
binding profiles of Esrrb at these regions. The middle panels in A-E show the 
Esrrb/DNA complex as detected by EMSA. All of these probes can form complexes 
with Esrrb proteins. Mutant probes on the other hand could not interact with Esrrb 
proteins. The sequences of the DNA probes and its respective mutants were listed in 
the bottom panels. The Esrrb binding motif was highlighted in red and the mutant 
nucleotide in blue. 
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regions of genes. The 3’ proximal and distal downstream regions contained 1,492 (8.5%) 
and 2,114 (12%) Esrrb binding clusters respectively. By using this criterion, a total of 
8,092 genes were defined as Esrrb target genes.  
 
To investigate the regulation of Esrrb on its target genes, I performed global gene 
expression profiling of the Esrrb-knockdown ES cells. RNA was harvested every two 
days in a 6-day experiment and was used to interrogate the Illunima microarray. 
Interestingly, 64% (5,196 genes) of the Esrrb target genes were differentially expressed 
upon Esrrb depletion in the 6-day interval (q value<0.05) (Figure 3.20). Among these 
differentially expressed Esrrb targets, various groups of genes involved in ES cell biology 
showed a reduction, no change or an induction in their transcription levels, which will be 
discussed in detail in the following sections. It was observed that Esrrb regulates its target 
genes in five regulation patterns (Figure 3.21). In regulation pattern 1, genes were down-
regulated on the 2nd day after Esrrb depletion, and this down-regulation persisted 
throughout the 6 days of the experiment (such as Kdelr3). Esrrb may play a key role in 
activating these genes. For regulation pattern 2, genes were down-regulated on the 2nd 
day after Esrrb depletion but this reduction was reversed in the following days (such as 
Edn1). The down-regulation on the 2nd day reflects a direct activating effect of Esrrb 
binding on this group of genes. The further reduction may be due to a redundancy effect 
from other activators of these genes. For regulation pattern 3, genes were induced 
throughout the 6-day experiment (such as E430036104Rik). These genes represent the 
repressed gene targets of Esrrb. For regulation pattern 4, genes were induced on the 2nd 
day of Esrrb depletion, but this induction was reversed and the gene expression was 
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reduced in the following days (such as Hoxb13). Regulatory pattern 2 and 4 may be the 
manifestation of indirect effects from Esrrb depletion over the 6-day experiments. 
Alternatively, other factors that also bind to these genes could modulate and affect the 
regulatory effects of Esrrb on its targets. For regulation pattern 5, Esrrb depletion did not 
result in expression changes (such as 4930451A13Rik). This could be explained by 




Figure 3.19 Distribution of Esrrb binding clusters was defined by their locations 
relative to a gene structure. A. Schematic diagram shows the locus annotation based on 
the relative positions in a transcription unit. Exons are depicted as blue boxes. The 
arrow indicates the direction of gene transcription. The loci within 10kb upstream or 
downstream of the nearest transcript units were defined as 5’proximal upstream or 
3’proximal downstream of genes respectively. The loci within the range of 10-100kb 
upstream or downstream of the nearest transcript units were respectively defined as 
5’distal upstream or 3’distal downstream of genes. The loci out of 100kb away from the 
nearest genes were defined as gene desert regions. B. The distribution of Esrrb binding 
clusters relative to the nearest transcript units. The ratios of the binding sites in 



















Figure 3.21 Different regulation patterns of Esrrb on its target genes. The x-axis 
represents the 6-day interval of Esrrb depletion. The y-axis represents the fold changes 
in gene expression levels which are computed as the ratio of the mRNA level in Esrrb-
depleted ES cells to the Gfp shRNA-transfected control cells. Five genes were 
presented as an example of each pattern. For regulation pattern 1, genes were down-
regulated on the 2nd day after Esrrb knockdown and this reduction in expression level 
lasted throughout the 6-day interval (such as Kdelr3). For regulation pattern 2, genes 
were down-regulated on the 2nd day after Esrrb knockdown but this reduction was 
reversed in the following days (such as Edn1). For regulation pattern 3, genes were 
induced throughout the 6-day interval (such as E430036104Rik). For regulation pattern 
4, genes were induced on the 2nd day of Esrrb knockdown. Unlike regulation pattern 3, 
this induction was reversed and the gene expression was reduced in the following days 
(such as Hoxb13). For regulation pattern 5, Esrrb knockdown did not result in any 



























genes after Esrrb 
knockdown 
5196 2896 12373 
Figure 3.20 Venn diagram showing the overlap between the Esrrb target genes and the 
differentially expressed genes during the 6-day interval after Esrrb knockdown (q 
value<0.05).  
Esrrb bound genes 
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3.4.4. Functional relevance of the target genes 
To further examine the functional relevance of the Esrrb target genes in ES cell biology, I 
performed gene ontology (GO) analysis (http://www.pantherdb.org./) and found that the 
target genes of Esrrb are involved in various functional processes (Table 3.2). In 
particular, I focused on the regulatory effects of Esrrb on the genes which were 







Table 3.2 Gene Ontology (GO) analysis was performed for functional annotation of 
Esrrb target genes (p value<0.01).  
  P-value 
Developmental processes 7.42E-07 
mRNA transcription regulation 7.71E-07 
mRNA transcription 1.19E-06 
Protein phosphorylation 1.37E-05 
Nucleoside, nucleotide and nucleic acid metabolism 3.04E-05 
Intracellular signaling cascade 1.34E-04 
Protein modification 1.53E-04 
Cell structure and motility 6.70E-04 
Mesoderm development 3.35E-03 
Stress response 4.96E-03 





Transcription factor 2.66E-05 
Molecular 
Function 
Protein kinase 7.87E-04 
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3.4.4.1. Esrrb binds to ES cell-associated genes 
The down-regulation of Esrrb using RNAi resulted in the differentiation of ES cells. I 
therefore speculated that one of the key mechanisms underlying the important role of 
Esrrb is its regulation of ES cell-associated genes. With reference to previous studies, I 
selected genes which play critical roles in ES cell maintenance or are preferentially 
expressed in pluripotent ES cells (Table 3.3) (Ramalho-Santos et al., 2002; Ivanova et al., 
2002; Mitsui et al., 2003; Loh et al., 2007). Interestingly, 20 out of the 25 selected genes 
are physically bound by Esrrb (Table 3.3). Only 5 genes, which include Ecat8, Dnmt3I, 
Nrob1, Pem and Pbmxrt, do not show Esrrb binding (Table 3.3). Most of the ES cell-
associated genes bound by Esrrb have multiple binding sites, while Hesx1, Gdf3, Eras, 
and Stat3 only have a single Esrrb binding site (Table 3.3). I randomly picked three genes, 
Esrrb, Oct4 and Sall4, to validate Esrrb binding by using the ChIP-qPCR method. A 
sharp peak with peak height of over 100 was observed in the intronic region of the Esrrb 
gene. Importantly, the binding can be validated by ChIP-qPCR. This suggests that Esrrb 
regulates the expression of its own encoding gene through an auto-regulatory loop 
(Figure 3.22). Sall4 is bound by Esrrb at multiple sites including the promoter and 
intronic regions (Figure 3.23). Two regions with the highest peak height were picked for 
validation using the ChIP-qPCR method. Interestingly, Sall4 has recently been reported 
to regulate the self-renewal of ES cells through the activation of Oct4 gene or as an 
interaction partner of Nanog (Zhang et al., 2006; Wu et al., 2006). In addition, four Esrrb 
binding clusters were detected in the promoter and enhancer regions of the Oct4 locus, all 
of which were validated by the ChIP-qPCR method (Figure 3.24). 
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Since the binding of a transcription factor on genes does not necessarily imply 
transcriptional regulation, I examined the expression profiles of these ES cell-associated 
genes in the Esrrb-depleted ES cells which have undergone shRNA treatments for 2, 4 or 
6 days. Most of the genes were significantly downregulated in the Esrrb-depleted ES 
cells, suggesting that Esrrb plays a positive regulatory role on their expression (Figure 
3.25). However, there are also ES cell-associated genes that were not affected in 
expression when Esrrb was depleted. Therefore, the binding of Esrrb to its gene targets 




Table 3.3 Summary of Esrrb binding to ES cell-associated genes. 
Genes Location of Esrrb binding sites 
Number of Esrrb 
binding sites 
5' proximal 1 2410004A20Rik/ecat1 3' proximal 1 
5' proximal 3 2410039E07Rik/ecat6 5' distal 1 
Eras in intron 1 
Esrrb in intron 11 
5' proximal 2 Fbxo15/ecat3 3' proximal 1 
Gdf3 in exon 1 
Hesx1 3' proximal 1 
Nanog 5' proximal 2 
5' proximal 3 Pou5f1 5' distal 1 
in intron 1 
5' proximal 2 Sall4 
5' distal 2 
5' proximal 1 
5' distal 1 
3' proximal 1 Sox2 
3' distal 3 
Stat3 5' proximal 1 
in intron 1 
5' distal 8 Tbx3 
3' distal 1 
in intron 4 
Tcfcp2l1 3' distal 2 
5' proximal 1 Tcl1 5' distal 1 
Tdgf1/cripto 5' proximal 2 
in exon 1 Utf1 3' proximal 2 
Zfp296 5' proximal 2 
5' proximal 1 Zfp42 5' distal 3 
Zfp57 5' proximal 2 
2410004F06Rik/ecat8 — — 
Dnmt3I — — 
Nrob1 — — 
Pem — — 








Figure 3.22 Esrrb binds to its encoding gene in ES cells. The upper panel shows the 
screen shot of the T2G browser presenting the binding profiles of Esrrb on the intron 
regions of its encoding gene. The red arrow shows the region picked for validation by 
ChIP-qPCR which was shown in the lower panel. A primer pair for this region without 


























Figure 3.23 Esrrb binds to the promoter and intronic regions of the Sall4 gene in ES 
cells. The upper panel shows the screen shot of the T2G browser presenting the binding 
profiles of Esrrb on the promoter region of Sall4 encoding gene. The red arrows (1-2) 
show the regions picked for validation by ChIP-qPCR which are shown in the lower 

























Figure 3.24 Esrrb binds to Oct4 gene in ES cells. The upper panel shows the screen 
shot of the T2G browser representing the binding profiles of Esrrb on the promoter 
region of Oct4 encoding gene. The red arrows (1-4) show the regions picked for 
validation by ChIP-qPCR which are shown in the lower panel. A primer pair for this 









































































Notably, among the ES cell-associated genes, Oct4, Sox2 and Nanog have been shown to 
be reprogramming factor encoding genes (Takahashi and Yamanaka, 2006; Maherali et 
al., 2007; Okita et al., 2007; Wernig et al., 2007; Yu et al., 2007). I am therefore 
particularly interested in examining the binding of Esrrb to the genes that encode other 
reprogramming factors. In addition to Oct4, Sox2 and Nanog, reprogramming factor 
encoding genes Klf2, Klf4, Klf5,  Myc and Mycn were also identified to be bound by 
Esrrb (Table 3.4) (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007; Yu et al., 























Figure 3.25 The regulation of Esrrb on the ES cell-associated genes. Heatmap shows 
the expression profile of the ES cell-associated genes which are bound by Esrrb. The 
genes are presented based on the fold changes of their expression levels after different 
days of Esrrb depletion (D2-6) compared with the Gfp shRNA-transfected control 
cells. They were sorted by the average expression ratio and mean centered. 
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expression (Figure 3.26). The microarray results showed that the expression of Klf4 and 
Klf5 were sensitive to the Esrrb level. In the Esrrb-depleted ES cells, these two genes 
were significantly and persistently downregulated during the entire six-day observational 
period. However, the expression level of Klf2 was unaltered upon the Esrrb knockdown, 
indicating the non-functional binding of Esrrb on this gene. For Myc, its expression was 
reduced by about 30% on the 2nd and 4th day of Esrrb depletion. The restoration of Myc 
expression levels on the 6th day indicates a possible compensation of activation by other 
regulators. Unlike Myc, I did not detect a differential expression of Mycn after the Esrrb 
depletion (Data not shown). 
 
In summary, Esrrb binds to many ES cell-associated genes and reprogramming factors. 
Since the majority of these bound genes are positively regulated by Esrrb, I speculated 
that the key mechanism by which Esrrb maintains the ES cell state is by sustaining the 








Figure 3.26 Expression profiles of reprogramming factors after Esrrb knockdown. The 
x axis represents different days of Esrrb knockdown and the y axis represents the gene 


























Table 3.4 Summary of Esrrb binding to reprogramming factor encoding genes. 
     
Genes Location of Esrrb binding sites Number of Esrrb binding sites 
5' distal 3 Klf2 
3' proximal  1 
3' proximal  1 Klf4 
3' distal 3 
Klf5 3' distal 3 
Myc 3' distal 1 
in intron 1 
3' proximal 1 Mycn 
3' distal 3 
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3.4.4.2. Regulatory relationship between Esrrb and Nanog 
The ChIP-sequencing mapping results revealed that Esrrb occupies two binding sites, 
located at the distal enhancer and proximal promoter regions of the Nanog gene (Figure 
3.27A). This observation is particularly interesting because Esrrb is also a target of 
Nanog. Moreover, the depletion of either Esrrb or Nanog results in the down-regulation 
of both corresponding genes (Figure 3.5D and 3.7C). I hypothesized that Nanog may be a 
key downstream effector of Esrrb’s function.  
 
First of all, I designed a series of primers along the 5.5 kb region upstream of the Nanog 
gene to validate the ChIP-sequencing results by the ChIP-qPCR method (Figure 3.27B 
and C). The depletion of Esrrb by shRNA and DES treatment led to the reduction of 
Esrrb binding at the Nanog loci, suggesting that the detected bindings are specific (Figure 
3.27D and E). Since Esrrb knockdown resulted in a decrease in the Nanog expression 
level by 50%, this indicates that Esrrb exerts a positive regulatory effect on Nanog 
expression. To further confirm the activating effect of Esrrb on the Nanog gene, I cloned 
the 5.5kb promoter region of the Nanog gene into the luciferase reporter vector (Figure 
3.28A). Co-transfection of this Nanog reporter construct with the Esrrb shRNA resulted 
in a strong reduction of the luciferase activity (Figure 3.28A). Conversely, when the 
Esrrb was overexpressed in either 293T or ES cells, the reporter activity driven by the 
Nanog promoter was induced significantly (Figure 3.28B and 3.28C). Importantly, 
overexpression of Esrrb in ES cells also induced the level of endogenous Nanog 
expression by at least 2 folds, while the expressions of Oct4 or Sox2 were not alerted by 
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Figure 3.27 Esrrb binds to Nanog gene. A. The screen shot of the T2G browser 
showing the binding profile of Esrrb on Nanog (AK010332) locus. The two peaks 
highlighted by red arrows correspond to the Nanog enhancer and proximal promoter. 
B. Schematic diagram showing the locations of the amplicons (black bars labeled 1-
15) that were used to detect ChIP-enriched fragments over the 5.5 kb Nanog promoter. 
Amplicons are numbered in order relative to their sites along the gene. The open box 
represents an exon. C. Real-time PCR validation of Esrrb binding to the Nanog gene. 
Fold enrichment is computed as the relative abundance of DNA fragments at the 
amplified region over a control amplified region. Data are presented as the mean ± 
SEM. D. Knockdown of Esrrb abolished the ChIP signal derived from anti-Esrrb 
antibody. Region 1, 2 and 12 were selected based on their high-fold enrichments of 
Esrrb binding. ES cells were transfected with control Luc shRNA, Esrrb shRNA 1 or 
Esrrb shRNA 2. Data are presented as the mean ± SEM. E. Esrrb bindings to the 
Nanog enhancer and proximal promoter regions were abolished upon DES treatment. 
Region 2 and 12 were selected for q-PCR. ChIP assay was performed with the samples 
of ES cells treated with 10uM DES or control 0.1% ethanol for two days. Data are 








































































































































Next, to address the question of whether Nanog is the key downstream effector of Esrrb 
in ES cell maintenance, I examined if an elevation of Nanog expression could rescue the 
differentiation induced by Esrrb knockdown. Since the Esrrb shRNA constructs confer 
puromycin resistance, I established a hygromycin-resistant Nanog overexpression 
construct. I generated an ES cell line that was transfected with this Nanog overexpression 
construct and maintained the cells in culture with hygromycin selection. The 
hygromycin-selected Nanog overexpression cell line displayed a great similarity to the F4 
cell line.  Moreover, it has ability to resist differentiation induced by either RA-treatment 
or LIF-withdrawal (Figure 3.29A).  
 
Interestingly, most of the cells maintained the colony morphology of ES cells when Esrrb 
was depleted in the Nanog-overexpressed cell line. In contrast, Esrrb knockdown in the 
mock overexpression cell line led to expected cell differentiation (Figure 3.29B). The 
Esrrb mRNA levels in both the cell lines were similar after Esrrb knockdown, thus the 
dissimilarity in cell morphology is not due to differences in knockdown efficiency 
Figure 3.28 Esrrb activates Nanog expression. A. The right panel shows the schematic 
digram of the luciferase reporter driven by the 5.5kb Nanog promoter. The effect of 
Esrrb RNAi on the Nanog promoter activity was tested by co-transfecting each Esrrb 
shRNA construct along with the Nanog promoter-Luc construct into ES cells. 
Luciferase activity was analyzed 2 days after transfection and is presented relative to 
the Gfp shRNA knockdown control. Data are presented as the mean ± SEM. B. Esrrb 
overexpression (OE) induced the Nanog promoter activity in a dosage-dependent 
manner in 293T cells. Data are presented as the mean ± SEM. C. Esrrb OE induced 
the Nanog promoter activity in ES cells. The SV40 promoter was used as a negative 
control. Data are presented as the mean ± SEM. D. In ES cells, Esrrb overexpression 
induced the expression of endogenous Nanog but not Oct4 or Sox2. The vector 
without Esrrb insertion was used as a mock overexpression control. Data are presented 
as the mean ± SEM. 
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(Figure 3.29C). At the molecular level, overexpression of Nanog effectively rescued the 
marker changes induced by the Esrrb knockdown (Figure 3.29D). The reduction in Rex1 
and Sox17 transcript levels were restored, while the induction of Fgf5 was suppressed. 
These results demonstrated that Nanog overexpression can rescue ES cell differentiation 
induced by Esrrb depletion. Through comparing the differentially regulated genes by 
Esrrb and Nanog through using the databases reported by a previous study, 436 genes 
were identified to be regulated by both of these two factors, supporting the overlapped 
roles in their functional pathways in ES cells (Appendix 2) (Ivanova et al., 2006) 
 
In summary, Nanog is the downstream target of Esrrb and its expression could be directly 
activated by Esrrb. In addition, overexpression of Nanog could partially rescue the 
differentiation induced by Esrrb depletion. Therefore, I concluded that the regulation of 
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3.4.4.3. Binding of Esrrb to the genes encoding for developmental regulators 
It was observed that the Nanog rescue on Esrrb depletion was only partial, as some 
differentiated cells were still observed. Thus the regulation of ES cell self-renewal and 
pluripotency by Esrrb is also mediated by some other Nanog-independent mechanisms. I 
next asked if Esrrb is also involved in the regulation of genes implicated in differentiation 
or development. Several gene families which have been reported for their roles in 
regulating developmental processes were selected for further analysis. These families 
include Forkhead box (Fox) proteins, Homeobox containing protein family (Hox), 
Myogenic basic domain (Myo) proteins, NK transcription factor related proteins (Nkx), 
Paired Box and paired-like proteins (Pax), Pou transcription factor family (Pou), SRY-
related HMG Box proteins (Sox), and T-box proteins (Tbx). Hox proteins function as 
transcriptional activators or repressors and are involved in numerous cellular processes 
including organogenesis, cellular differentiation, cell adhesion and migration, cell cycle 
and apoptosis (Svingen and Tonissen, 2006). Sox proteins are widely involved in 
developmental processes such as neuronal development, sex determination and 
Figure 3.29 Overexpression of Nanog can rescue the differentiation induced by Esrrb 
knockdown. A. Characterization of the hygromycin resistance Nanog overexpression 
cell line. Nanog-overexpressed ES cells (OE) and control ES cells were grown in the 
presence 0.3 μM RA (+RA) or no RA (-RA) for 48 hours, or in the presence of LIF 
(+LIF) or absence of LIF (-LIF) for 60 hours. B. ES cells with constitutive Nanog 
overexpression were challenged with shRNA-directed Esrrb knockdown for 3 days. 
C. Esrrb was similarly depleted both in Nanog-overexpressed (Nanog OE) and vector 
control ES cells. Data are presented as the mean ± SEM. D. Nanog overexpression 
reduced the down-regulation of Nanog, Oct4, Rex1 and Sox17 upon the Esrrb 
depletion. On the other hand, it compensated for the loss of Esrrb function by reducing 
the induction of differentiation markers Fgf5, but not Msx1. The levels of the 
transcripts were normalized against control plasmid transfected cells. Data are 
presented as the mean ± SEM
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lymphocyte development (Kiefer, 2007). Pax proteins are tissue specific transcription 
factors containing a PAIRED domain and a homeodomain, which are important in early 
tissue specification of embryos (Lang et al., 2007). They are also related with limb 
regeneration (Lang et al., 2007). Unexpectedly, Esrrb binds to diverse classes of 
developmental genes mentioned above (Table 3.5). One notable example is the binding of 
Esrrb to the Sox17 gene (Figure 3.30). The validation by ChIP-qPCR confirmed the 
interaction of Esrrb with the Sox17 gene (Figure 3.30). Sox17 is a well-established 
endoderm marker gene. Another endoderm gene Gata6 was also bound by Esrrb as 
shown in the ChIP-sequencing and ChIP-qPCR results (Figure 3.31). These results imply 




Table 3.5 Summary of Esrrb binding to developmental genes. 
Hox Fox Tcf Sox Myo Tbx Nkx Pax Pou 
Hoxa1 Foxa1 Tcf12 Sox11 Myo10 Tbx1 Nkx1-2 Pax1 Pou2f2
Hoxa10 Foxa2 Tcf15 Sox12 Myo15 Tbx2 Nkx2-3 Pax2 Pou2f3
Hoxa11 Foxa3 Tcf19 Sox13 Myo18a Tbx20 Nkx6-1 Pax6 Pou4f2
Hoxa13 Foxb2 Tcf2 Sox17 Myo1b Tbx21 Nkx6-2 Pax7 Pou5f1
Hoxa5 Foxc2 Tcf21 Sox18 Myo1e Tbx3 Pax8 
Hoxa6 Foxd1 Tcf3 Sox2 Myo1f Tbx4 Pax9 
Hoxb1 Foxd2 Tcf4 Sox3 Myo1g Tbx5 
Hoxb13 Foxd3 Tcf7 Sox4 Myo5b 
Hoxb4 Foxd4 Tcf7l2 Sox5 Myo6 
Hoxb5 Foxf1a Sox6 Myo7a 
Hoxb9 Foxi1 Sox8 Myocd 
Hoxc12 Foxj1 Sox9 Myog 
Hoxc13 Foxj2 Myom2 
Hoxc4 Foxj3 Myot 













Figure 3.30 Esrrb binds to the intronic region of Sox17 gene in ES cells. The upper 
panel is the screen shot of the T2G browser showing the binding profiles of Esrrb on 
the promoter region of Sox17 gene. The red arrow indicates the region picked for 
validation by ChIP-qPCR which is shown in the lower panel. A primer pair for this 























Figure 3.31 Esrrb binds to Gata6 gene in ES cells. The upper panel is the screen shot 
of the T2G browser showing the binding profiles of Esrrb on the promoter region of 
Gata6. The red arrows indicate the peak sites used for validations. The binding of Esrrb 
to Gata6 gene was validated by Esrrb ChIP-qPCR (lower panel). Two peak regions 
indicated by 1 and 2 were picked for ChIP-qPCR. A primer pair for this region without 



































I further checked the regulatory effect of Esrrb on these developmental genes by 
expression profiling. I found that Esrrb exerts different forms of transcriptional 
regulations on these genes (Figure 3.32). For example, Esrrb knockdown led to the 
reduction in expression of Hox genes (Hoxa7, Hoxb13, Hoxc13 and Hoxc4) and Myo 
genes (Myo18a, Myo1f, Myo1g, Myo7a and Myom2) while it resulted in an induction of 
Fox gene expression (Foxa2, Foxd4 and Foxo1) and Sox gene family (Sox11, Sox13, 
Sox18, Sox4 and Sox9). In some cases, members of the same gene family can be 
regulated differentially by Esrrb. One notable example is Tbx gene family where Esrrb 
activates the expression of Tbx3 but represses Tbx4 expression. On the other hand, for the 
Tcf, Nkx and Pou gene families, Esrrb depletion did not lead to any obvious changes in 







Importantly, endoderm genes (Sox17 and Gata6) (Figure 3.30 and 3.31), Mesendoderm 
markers (Msx1), ectoderm marker (Fgf5) and trophectoderm regulators (Hand1 and Cdx2) 
were all occupied by Esrrb (Table 3.6). Thus Esrrb has an important regulatory role in 
controlling the expression of key lineage genes, thereby preventing differentiation and 
maintaining the pluripotent state of ES cells (Table 3.6; Figure 3.7D). 
Figure 3.32 The regulation of Esrrb on developmental genes. Heatmaps showing the 
expression profile of the developmental genes which were bound by Esrrb. The genes 
were presented based on the fold changes of their expression levels after different 
days (D2-6) of Esrrb depletion compared with the Gfp shRNA-transfected cell 
control. They were sorted by the average expression ratio and mean centered. 





3.4.4.4. Esrrb binds to the genes encoding for epigenetic modifiers 
Due to the importance of epigenetic processes in ES cell maintenance (Montgomery et al.,  
2005; Bernstein et al.,  2006; Azuara et al.,  2006; Lee et al.,  2006; Pasini et al.,  2007), I 
was interested to know whether Esrrb is involved in regulating the epigenetic processes 
via the control of expression of epigenetic regulators.  
 
Firstly, I sought to identify the binding of Esrrb to epigenetic regulator encoding genes 
which have been shown to be critical for ES cell derivation from the embryo or the 
maintenance of the ES cell state (summarized by Surani et al, 2007). These genes include 
Brg1 (Bultman et al., 2000; Bultman et al., 2006), CAF-1 (Houlard et al., 2006), Dicer1 
(Bernstein et al., 2003), Dnmt3L (Bourc’his et al., 2001; Okano et al., 2002), Eed 
(Shumacher et al., 1996), Ezh2 (O’Carroll et al., 2001), Hdac1 (Lagger et al., 2002), 
Gcn5 (Xu et al., 2002), Mll/All-1 (Yu et al., 1995; Yagi et al., 1998; Glaser et al., 2006), 
Table 3.6 Summary of Esrrb binding to lineage marker genes. 
    
Genes Location of Esrrb binding sites Number of Esrrb binding sites 
Msx1 5' distal 1 
Fgf5 5' distal 1 
5' proximal 1 Hand1 
5' distal 3 
in intron 1 Cdx2 
3' proximal 1 
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Mbd3 (Hendrich et al., 2001; Kaji et al., 2006), Nasp (Richardson et al., 2006), Npm2 
(Burns et al., 2003), Setdb1 (Dodge et al., 2004), Smarcb1 (Klochendler-Yeivin et al., 
2000), Suz12 (Pasini et al., 2004), YY1 (Donohoe et al., 1999). Interestingly, 6 of them, 
Dicer, Eed, Hdac1, Mbd3, Suz12 and Smarcb1 were targeted by Esrrb. However, despite 
the binding, none of them were downregulated alongside with the knockdown of Esrrb.  
 
Secondly, I focused on the JmjC domain-containing proteins. Several of JmjC domain-
containing proteins have been reported to be function as histone demethylases (Yamane 
et al., 2006; Tsukada et al., 2006; Klose et al., 2006; Klose and Zhang, 2007). Recently, 
JmjC domain-containing protein encoding genes, Jmjd1a and Jmjd2c have been reported 
to be critical for the self-renewal of ES cells as the downstream targets of Oct4 (Loh et al., 
2007). Even though no binding of Esrrb was found on these two genes, several genes that 
encode JmjC domain-containing proteins were targeted by Esrrb. They include Jarid1b, 
Jarid2, Jmjd2b, Jmjd3 and Jmjd4 (Table 3.7). Although the expression profiling indicates 
that Jmjd2b and Jarid1b were only down-regulated on the 6th day of Esrrb knockdown 
(Data not shown), Jmjd3 appeared to be sensitive to the Esrrb level (Figure 3.33). Its 
expression was reduced on the 2nd day of Esrrb depletion and this reduction lasted in the 
following days, suggesting the activating effect of Esrrb on this gene. Jmjd3 is a novel 
histone H3K27 demethylase that participates in cell fate decisions and developmental 
processes by antagonizing polycomb protein-mediated gene silencing (Hong et al., 2007; 
Jepsen et al., 2007; Xiang et al., 2007; Lan et al., 2007; De Santa et al., 2007; Agger et 
al., 2007). However, the role of Jmjd3 in ES cells remains unclear. If Jmjd3 could 
antagonize the polycomb protein-mediated gene silencing in ES cells (Lan et al., 2007; 
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De Santa et al., 2007; Agger et al., 2007), it could potentially be involved in pluripotency 
decisions through its regulation on lineage-related genes.  Thus as an activator of Jmjd3, 





Table 3.7 Summary of Esrrb binding to epigenetic regulator encoding genes. 
Genes Location of Esrrb binding sites Number of Esrrb binding sites 
in intron 3 
5' proximal 1 
5' distal 1 
Jarid1b 
3' proximal 1 
in intron 5 
5' proximal 1 Jarid2 
5' distal 7 
Jmjd2b in exon 1 
Jmjd3 in intron 2 
in exon 1 Jmjd4 





3.4.4.5. Esrrb, Nanog and Oct4 co-occupy common target genes 
To further examine the roles of Esrrb in the pluripotent regulatory network, I compared 
the overlaps between the Esrrb target genes with the targets of Nanog and Oct4 identified 
previously from the ChIP-PET study (Loh et al., 2006). A comparison of the genes bound 
by Esrrb, Nanog and Oct4 revealed that the three transcription factors have overlapping 
yet distinct downstream targets. 51% of Oct4 target genes and 41% of Nanog target genes 
were also targeted by Esrrb. A total of 253 genes were found to be common targets of all 
the three transcription factors (Figure 3.34; Appendix 4). Among these 253 genes are ES 
cell-associated genes like Oct4, Sox2, Nanog, Esrrb, Tcfcp2l1, and Tbx3. The co-binding 
of Esrrb, Nanog and Oct4 on these self-renewal genes suggests the importance of 
maintaining their high expression levels in ES cells. In addition, some developmental 















Figure 3.33 Expression profile of Jmjd3 after Esrrb depletion. The x axis represents 
different days of Esrrb depletion (D2-6) and the y axis represents the gene expression 
fold change based on the microarray data after Esrrb depletion as compared to the 
knockdown control. 
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be bound by these three transcription factors. Interestingly, two epigenetic regulators, 
Suz12 and Jarid2 were co-occupied by Esrrb, Oct4 and Nanog. This potentially implies 
the crosstalk between genetic and epigenetic regulators in ES cell maintenance.  
Strikingly, 12 common target genes of Oct4 and Nanog previously found to be conserved 
in human and mouse ES cells were occupied by Esrrb (Loh et al., 2006). These 12 genes 
are Nanog, Sox2, Zic3, Eomes, Rif1, Rest, Cdyl, Jarid2, Gsh2, Smarcad1, Atbf1 and Sall1. 
This interesting result suggests that Esrrb is intricately involved in regulating genes that 
are also bound by the “master regulators” Oct4 and Nanog. Furthermore, through 
comparing the differentially expressed genes in Esrrb-depleted, Nanog-depleted and 
Oct4-depleted ES cells, 10 common target genes of Esrrb, Nanog and Oct4 were found to 
be functionally regulated by all these three transcription factors. These 10 genes include 
5033405K12Rik, 9630008K15Rik, Btbd11, Dkk1, Egln3, Fzd5, Jam2, Lpp, Manba and 
Otx2 (Ivanova et al., 2006). The results indicate that the three factors may function in 
distinct pathways but operate inter-dependently to coordinate the specification of the ES 
cell state. To further uncover the functional relevance of these overlapped targets shared 
among Esrrb, Oct4 and Nanog, I performed GO analysis for these genes (Table 3.8). 
Notably, these targets are significantly over-represented in the cellular processes of 
transcription regulation and developmental processes.   
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Nanog bound genes 
Figure 3.34 Venn diagram showing the overlaps of target genes bound by Esrrb, Oct4 or 
Nanog.  
Table 3.8 Gene Ontology (GO) analysis was performed for functional annotation of the 
overlapped genes bound by Esrrb, Oct4 and Nanog (p value<0.01).  
  P-value 
Developmental processes 5.99E-08 
mRNA transcription 2.16E-05 
mRNA transcription regulation 8.60E-05 
Biological Process 
Nucleoside, nucleotide and nucleic 
acid metabolism 3.98E-04 
























Chapter IV. Discussion  
In this project, Esrrb was identified as a novel downstream target of the ES cell regulator 
Nanog. The Esrrb-depleted ES cells differentiated into fibroblast-like cells, along with 
the reduction in pluripotent gene expression and the induction of differentiation marker 
gene expression. Through genome-wide mapping of Esrrb binding sites and expression 
profiling of the Esrrb knockdown cells, the roles of Esrrb in maintaining the 
undifferentiated state of ES cells were dissected. Hence, this project provides greater 
understanding into the mechanisms that underlie the important roles of Nanog and Esrrb 
in ES cell maintenance.  
 
4.1. Nanog target genes as candidate regulators of the self-renewal and pluripotency 
of ES cells 
In this project, the genes positively regulated by Nanog were identified as candidate 
factors that may function in maintaining the pluripotent state of ES cells. The rationale 
behind this strategy was based on the critical roles of Nanog in maintaining ES cells and 
in early embryonic development (Mitsui et al., 2003). Independent studies by other 
groups have also confirmed the role of Nanog in self-renewal, where the down-regulation 
of Nanog resulted in extensive differentiation of ES cells (Ivanova et al., 2006).  
 
The functional significance of Nanog was re-evaluated in a recent study by Chambers et 
al. (2007). They demonstrated that Nanog-/- ES cells can remain undifferentiated while 
maintaining the capacity to differentiate in vitro and contribute to in vivo lineages via the 
formation of chimeras. Hence, the report concluded that Nanog was dispensable for 
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somatic pluripotency (Chambers et al., 2007). However, several questions arise from the 
study of Chambers et al. (2007). Firstly, the previous work by Mitsui et al. (2003) has 
demonstrated the requirement of Nanog for ES cell derivation from the ICM. Importantly, 
homozygous Nanog knockout ES cells exhibited phenotypic differentiation, characteristic 
of endoderm lineage. Molecular marker analysis also showed down-regulation of 
pluripotent marker expression (such as Oct4) and up-regulation of differentiation marker 
expression. Notably, Mitsui et al. (2003) used the RF8 mouse ES cell line and targeted 
the second exon of the Nanog gene. On the other hand, Chambers et al. (2007) used the 
E14 mouse ES cell line and performed conditional knockout through targeting the region 
from intron 1 to the 3’ UTR of the Nanog locus under the tamoxifen-inducible control. 
Whether the disparities in the results between the two studies can be accounted for by the 
use of different ES cell lines and knockout strategies remains to be answered. Secondly, 
even though the heterogeneous expression of Nanog in ES cell culture as shown by 
Chambers et al. (2007) is supported by the work from Singh et al (2007), the two studies 
arrived at a very different conclusion on the regulation of downstream genes. In the study 
of Chambers et al. (2007), it was found that Nanog-/- ES cells expressed normal level of 
Oct4, Sox2 and Rex1. Remarkably, Singh et al (2007) reported the dramatic reduction of 
Oct4, Sox2 and Rex1 expression in ES cell population that were sorted for low Nanog 
expression. This raised a question whether the Nanog-null ES cells of Chambers et al. 
(2007) have acquired compensatory changes or mutations during the selection process. 
Thus it will be necessary to further characterize these Nanog-null ES cells for normal 
karyotype and genomic integrity. Nevertheless, the study of Chambers et al. (2007) 
showed great consistency in revealing the role of Nanog in maintaining the 
 135
undifferentiated state of the ES cells. Nanog-/- ES cells have reduced self-renewal 
capacity and a propensity to differentiate spontaneously in culture (Chambers et al., 
2007). Furthermore, Nanog-/- ES cells are impaired in germline transmissions. Together, 
this suggests that Nanog has a role in maintaining the undifferentiated state of ES cells 
and is required for the ES cell pluripotency.  
 
Besides Esrrb, other downstream targets of Nanog have previously been shown to play 
roles in ES cell maintenance. These genes include FoxD3, Rif1, Zic3 and Sall4 (Hanna et 
al, 2002; Guo et al, 2002; Loh et al, 2006; Lim et al, 2006; Wu et al, 2006; Zhang et al, 
2006). FoxD3 generally functions as a repressor and is critical for the ICM and epiblast 
formation in vivo and for the pluripotent stem cell maintenance in vitro (Hanna et al, 
2002; Guo et al, 2002). Rif1 and Zic3 are indispensable for pluripotent ES cells, as 
shRNA-mediated depletion of Rif1 or Zic3 leads to ES cell differentiation (Loh et al., 
2006; Lim et al., 2006). Two studies demonstrated the importance of Sall4 in ES cells 
(Zhang et al., 2006; Wu et al., 2006). Notably Sall4 activates Oct4 expression (Zhang et 
al., 2006) and at the same time interacts with Nanog to co-regulate many downstream 
target genes (Wu et al., 2006). Hence, the Nanog transcriptional network serves as a 
useful guide for identifying additional components involved in the regulation of the self-
renewal, pluripotency and differentiation of ES cells. The identification of the role of 
Esrrb in ES cell maintenance validates the importance of the Nanog network for the 




4.1.1. Esrrb is a nuclear receptor protein that is critical for ES cell maintenance.  
Esrrb is a nuclear receptor protein, belonging to the estrogen related receptor protein 
(ERR) family. Because natural ligands of this class of nuclear receptor proteins have not 
been identified, they are also known as orphan nuclear receptors (Giguère, 1999). 
Sequence comparison analysis revealed that ERRs are close relatives of the estrogen 
receptors (ERs) (Giguère, 2002). ER genes include three members, ERα, ERβ and ERγ 
(Xia et al., 1999; Green et al., 1986). ERs contain the conserved domains A to F common 
to nuclear receptors and regulate gene expression through recognition of a specific 
enhancer known as the estrogen responsive element (ERE) with the consensus sequence 
of 5’-AGGTCAnnnTGACCT-3’ (Beato et al., 1989; Rollerova et al., 2000). In contrast 
to ERRs, ERs are responsive to the natural ligand, estradiol (Green et al., 1986; Tremblay 
et al., 1999). ERRs consist of ERRα, ERRβ/Esrrb and ERRγ (Giguère et al., 1988; Heard 
et al., 2000). Similar to most nuclear receptors, ERRs possess a well-conserved DNA-
binding domain (C domain), ligand-binding domain (E domain) and the less conserved 
transactivation domain (N-terminal domain) (Giguere, 2002). Although they do not 
respond to estradiol, ERRs can recognize the ERE or estrogen related responsive element 
(ERRE) (5’-TCAAGGTCA-3’) and bind either as dimers or monomers (Hong et al., 
1999; Bonnelye et al., 1997; Vanacker et al., 1998; Lu et al., 2001; Vanacker et al., 1999; 
Xie et al., 1999; Zhang and Teng, 2000; Yang et al., 1998; Sanyal et al., 2002; Pettersson 
et al., 1996; Sladek et al., 1997; Johnston et al., 1997; Yang et al., 1996; Vanacker et al., 
1999). Apart from the ERRs and ERs, other nuclear receptor, such as steroidogenic 
factor-1 (SF-1; NR5A1) can also bind to the ERRE (Wilson et al., 1993; Luo et al., 1994). 
Therefore extensive crosstalk exists between ERs, ERRs and other classes of nuclear 
 137
receptors in the transcriptional regulation of downstream target genes (Yang et al., 1996; 
Vanacker et al., 1999). In mouse embryonic stem cells, Esrrb (also known as ERRβ) is a 
predominant estrogen receptor related protein that is highly expressed, whereas the 
expressions of ERRα and ERRγ are very low.  
 
Expression of Esrrb in the mouse embryo is restricted to the extra-embryonic ectoderm 
and the early stages of chorion formation (Luo et al., 1997). Esrrb transcript is first 
detected in the extra-embryonic ectoderm at E5.5. At E6.5, its expression becomes more 
prominent. By E8.5, however, Esrrb expression starts to diminish and becomes 
undetectable at the later stages of embryonic development (Luo et al., 1997). Expression 
of Esrrb beyond the embryonic stages is not well-studied and remains an area for further 
exploration. Knockout of Esrrb in mice results in abnormal chorion formation, failure in 
trophoblast proliferation, and consequentially embryonic lethality at E10.5 due to 
abnormalities of the placenta (Luo et al., 1997). Failure of the Esrrb knockout embryo to 
proceed beyond early developmental stages provides evidence of its functional 
importance in embryonic development. A recent study showed that Esrrb expression 
persisted in embryonic germ cells at E11.5 (Mitsunaga et al., 2004). Mitsunaga et al. 
have also shown that conditional Esrrb mutant embryos gave rise to fewer germ cells 
(Mitsunaga et al., 2004). Germ cells are a highly specialized cell type that closely 
resembles the pluripotent ES cells. Embryonic germ cells derived from the primordial 
germ cells have great developmental potential and can contribute efficiently to chimeras 
(Labosky et al., 1994, Stewart et al., 1994).  
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In ES cells, the expression of Esrrb is up-regulated (Wei et al., 2005; Pettersson et al., 
1996). Its expression is inhibited during differentiation induced by LIF withdrawal 
(Palmqvist et al., 2005). Hence, the expression of Esrrb is positively correlated with the 
pluripotent state of the ES cells. During the shRNA-mediated Esrrb knockdown, ES cells 
became flattened and adopted the appearance of fibroblasts with a loss of alkaline 
phosphatase staining. Consistent with this differentiation phenotype, expression analysis 
of marker genes revealed that the expression of ES cell-specific genes was reduced in 
Esrrb-depleted cells, whereas that of multiple lineage markers was induced. These results 
suggested a previously uncharacterized role of Esrrb in maintaining the self-renewing 
state of ES cells.  
 
Previously, Ivanova et al. performed stable knockdown of Esrrb using RNAi and 
confirmed its role as a regulator of the ES cell self-renewal (Ivanova et al., 2006). Using 
a fluorescence-based competition assay, they demonstrated that Esrrb is a gene important 
for self-renewal. Consistent with my findings, Ivanova et al. showed that depletion of 
Esrrb led to ES cell differentiation and resulted in the induction of various lineage marker 
expressions (Ivanova et al., 2006). However, in their study, the expression of 
trophectoderm lineage markers was not affected during the 8-day Esrrb depletion 
experiment. Instead, Esrrb depletion resulted in the induction of endoderm marker 
expression. These observations contradict the findings in this thesis, where trophectoderm 
markers were activated and endoderm genes were suppressed in the Esrrb-depleted ES 
cells. It is noteworthy that the mock knockdown control cells used in the study of Ivanova 
et al. seem to induce spontaneous perturbation of lineage markers, including endoderm 
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markers (Ivanova et al., 2006). Thus it is conceivable that the differences in the two 
studies pertaining to lineage marker expression levels could be due to the dissimilarity in 
the behaviors of the control cells used. To further elucidate and characterize the 
mechanisms underlying the role of Esrrb in pluripotency, a microarray time course 
experiment (1 to 7 days) was performed on the Esrrb knockdown ES cells (Ivanova et al., 
2006). From the gene expression profiles of the shRNA-mediated knockdown cells, they 
hypothesized that the mechanisms by which Esrrb maintains self-renewal may include 
the direct repression of differentiation-promoting genes (Ivanova et al., 2006). This 
corroborated well with my findings that Esrrb binds extensively to developmental genes 
and regulates their expression. The genome-wide analysis in this project also uncovers 
many previously unknown regulatory nodes that link Esrrb to genes with diverse cellular 
functions including self-renewal, chromatin modifications, and reprogramming process. 
These will be further discussed in the following sections. Recently, by using a 
computational approach, Zhou et al. identified a list of 15 core regulators in mouse ES 
cells which include Oct4, Nanog, and Esrrb. This further highlights the important role of 
Esrrb in the transcriptional network regulating the maintenance of ES cell self-renewal 
and pluripotency (Zhou et al., 2007).  
 
4.2. Relationship between Esrrb and the key ES cell regulators 
As a downstream target of Nanog and Oct4, Esrrb is directly bound and positively 
regulated by these two key transcription factors (Loh et al., 2006). It was previously 
reported that Oct4 regulates Nanog expression in ES cells (Rodda et al., 2005; Kuroda et 
al., 2005). Knockdown of Oct4 also reduced the reporter expression driven by the Nanog 
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promoter (Rodda et al., 2005). Nanog is also functionally linked to Oct4 through 
regulating their common downstream targets to prevent ES cells from differentiation 
(Loh et al., 2006). In addition, Nanog knockdown resulted in the drastic reduction of 
Oct4 expression. Moreover, overexpression of Nanog in ES cells can sustain the level of 
Oct4 expression under RA-induced differentiation condition. Interestingly, the Esrrb 
ChIP-sequencing results uncovered a novel link between Esrrb and the Nanog and Oct4 
genes (Figure 4.1). In particular, depletion of Esrrb can reduce Nanog expression while 
forced expression of Esrrb induced Nanog promoter activity. The close relationship 
between Esrrb, Nanog and Oct4 extends to their overlapped target genes. The 
combinatorial regulation of common targets may provide robust and rapid response to 
developmental signals in the processes of embryonic development. 
 
Two regulatory motifs can be use to define the transcriptional network formed by Esrrb, 
Nanog and Oct4. The feed-forward loop describes the observation that Oct4 and Nanog 
converge on Esrrb and regulate its expression, which in turn act in concert with these two 
factors to control downstream target genes. The feed-forward loop motif may confer 
stability to the system and allow for rapid response to developmental switching 
depending on the activities of the individual factors in the loop. Esrrb, Nanog and Oct4 
bind to the regulatory elements of their own genes (Figure 4.1) (Loh et al., 2006), thus 
forming an interconnected auto-regulatory loop. In this auto-regulatory loop, the 
expression and function of these three key stem cell factors are linked to one another. 
Auto-regulation is thought to provide several advantages, including reduced response 






The close inter-connected relationship between Esrrb, Nanog and Oct4 is supported by 
recent studies. Wang et al. used affinity purification coupled with mass-spectrometry to 
identify Esrrb as a member of the Nanog interactome. Sall4 is also a member of the 
Nanog interactome (Wang et al., 2006). Using ChIP analysis, Wu et al. demonstrated that 
there are considerable overlap in the binding sites of Nanog and Sall4, suggesting co-
regulation of downstream target genes (Wu et al., 2006). Thus it is reasonable to envisage 
that Esrrb and Nanog may function as partners in regulating common downstream targets 
in ES cells. Another key observation in the study of Wang et al. is that members of the 
interactomes are also targets of Nanog and/or Oct4 (Wang et al., 2006). What emerges is 
a pluripotency network that is tightly inter-regulated and intricately connected by protein-
protein interactions. Interestingly, I found that many genes in the interactome are also 
targeted by Esrrb, such as Nanog, Oct4, Sall4, Rif1, Rest, Esrrb and Dax1. Thus the 
findings here place Esrrb as an important member in the tight protein 
interactome/regulatory networks that govern ES cell self-renewal. In summary, the tight 
Figure 4.1 The interconnected regulatory loop formed by Esrrb, Nanog and Oct4. 
Esrrb, Nanog and Oct4 can target each other’s encoding gene, while each of them 
auto-regulates their own expression (Loh et al., 2006).  
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interconnected circuitry formed by Esrrb, Oct4 and Nanog suggests the robust and 
concerted regulatory effects of these three factors in maintaining undifferentiated ES cells.  
 
4.3. The Esrrb network is highly enriched in self-renewal and developmental genes 
The work by Ivanova et al. has identified several self-renewal genes including Nanog, 
Oct4, Sox2, Tbx3, Esrrb, Tcl1, Dppa4, Mm.343880, Mm.276044 and Mm.219358 
(Ivanova et al., 2006). In particular, knockdown of Nanog, Oct4, Sox2, Tbx3, Esrrb, Tcl1 
or Dppa4 led to the loss of alkaline phophatase staining suggesting that these genes are 
required for the maintenance of ES cell state. Interestingly, these factors were identified 
by this study as targets of Esrrb. Moreover, from expression profile analysis, Nanog, 
Sox2, Tbx3 and Tcl1 were found to be positively regulated by Esrrb. Thus Esrrb plays a 
positive role in the regulation of the newly identified self-renewal regulators. In their 
study, Ivanova et al. have only identified a role for Esrrb in regulating the self-renewal of 
ES cells. The findings in this thesis provide novel functional mechanisms for Esrrb to 
regulate the expression of critical downstream self-renewal regulators, thereby 
maintaining the pluripotency of ES cells.   
 
Two groups have recently reported the construction of the Oct4 and Nanog 
transcriptional regulatory networks in human and mouse embryonic stem cells 
respectively (Boyer et al., 2005; Loh et al., 2006). These studies have found that both 
Oct4 and Nanog bind extensively to genes involving in developmental processes (Boyer 
et al., 2005; Loh et al., 2006). Expression profile analysis in the study of Ivanova et al. 
revealed that several developmental genes are preferentially up-regulated in the Oct4 and 
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Nanog knockdown cells (Ivanova et al., 2006). These genes include Otx2 and Pitx2 
which induced ES cells differentiation when over-expressed (Ivanova et al., 2006). 
Interestingly, Otx2 was previously identified to be a gene target of both Nanog and Oct4, 
whereas Pitx2 seem to be regulated by Nanog (Boyer et al., 2005; Loh et al., 2006). Thus 
one strategy that Oct4 and Nanog may maintain pluripotency is by promoting the 
expression of downstream self-renewal genes while simultaneously repressing the 
activity of differentiation-promoting genes.  
 
Similar with Oct4 and Nanog, many target genes of Esrrb were uncovered to have 
functions in differentiation and developmental processes. Esrrb binds to the endoderm 
gene, Gata6, and trophectoderm regulator, Cdx2. Previous studies performed by forced-
expression of sole transcription factors such as Gata6 or Cdx2 in ES cells (Fujikura et al., 
2002; Niwa et al., 2005) demonstrate that they are sufficient to induce endodermal and 
trophectodermal differentiation respectively. Forced expression of Otx2, Pitx2, Sox18, 
Snai1, Ets2, Irx3 and Sox9 in ES cells resulted in differentiated phenotypes (Ivanova et 
al., 2006). Interestingly, my study identified the binding of Esrrb to all of these 
developmental genes and controlling their expression (Table 4.1; Figure 4.2). Thus, Esrrb 
appears to regulate differentiation-associated and lineage marker gene expressions in ES 
cells. This suggests that the mechanisms by which Esrrb maintains pluripotency may 








4.4. The regulation of the ES cell chromatin structures by Esrrb  
The recent study by Loh et al. presented a novel mechanism whereby Oct4 can activate 
its target genes indirectly through regulating the expression of chromatin modifiers. 
These chromatin modifiers maintain the gene expression by ensuring the accessible 
Figure 4.2 The regulation of differentiation-associated genes by Esrrb. Heatmap 
showed the expression profile of these genes which are bound by Esrrb. The genes 
were presented based on the fold changes of their expression levels after different 
days (D2-6) of Esrrb depletion compared with the Gfp shRNA-transfected control 
cells. They were sorted by the average expression ratio and mean centered. 
Table 4.1 Summary of Esrrb binding to differentiation-related genes. 
Genes Location of Esrrb binding sites Number of Esrrb binding sites 
Otx2 3' proximal 2 
Pitx2 in intron 1 
Sox18 3' proximal 1 
in exon 1 
5' proximal 1 
3' proximal 1 
Snai1 
3' distal 1 
5' distal 1 Ets2 
3' distal 2 
Irx3 5' distal 1 










chromatin conformation at the sites of the Oct4 target genes. For example, Tcl1 is 
regulated by a histone H3K9 demethylase Jmjd1a (JmjC domain containing protein 1a) 
which in turn is transcriptionally regulated by Oct4 (Loh et al, 2007). This study connects 
the ES cell transcription circuitry to epigenetic modifiers to specify the pluripotent 
epigenetic landscape.  
 
In finding the answers to whether Esrrb may also regulate chromatin modifier encoding 
genes that could potentially specify the epigenetic processes in the ES cells, I uncovered 
the Esrrb bound genes that encode for chromatin modifying enzymes, Dicer, Eed, Hdac1, 
Mbd3, Suz12 and Smarcb1. These genes have previously been ascribed roles in regulating 
ES cell self-renewal or pluripotency (Bernstein et al., 2003; Shumacher et al., 1996; 
Lagger et al., 2002; Hendrich et al., 2001; Kaji et al., 2006; Pasini et al., 2004; 
Klochendler-Yeivin et al., 2000; Boyer et al., 2006). Although retaining the ability to 
self-renew, the Mbd3-null ES cells lost the capability to differentiate into somatic lineage 
cells (Kaji et al., 2006). Similarly, Eed-null or Suz12-null ES cells appear to retain 
normal self-renewing capacity, but are impaired in their ability to differentiate 
(Montgomery et al., 2005; Azuara et al., 2006; Lee et al., 2006). Eed and Suz12 are part 
of the Polycomb repressive complex (PRC) that appear to play an important role in 
specifying the epigenetic landscape of pluripotent ES cells (Boyer et al., 2006; Lee et al., 
2006). However, expression profiling suggests that the binding of Esrrb to these sites 
may not be functional. One possible explanation is that the expression of these epigenetic 
regulators is critical for the ES cell self-renewal and pluripotency; therefore they are 
under tight regulatory control. Thus the removal of a single factor (such as Esrrb) may be 
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insufficient to perturb their expression. Multiple transcription factors that bind to a single 
gene may have redundant effects in regulating the expression of the target. It is 
noteworthy that similar with Esrrb, Oct4 and Nanog only functionally regulate a subset of 
their target genes (Loh et al., 2006). Since Esrrb shares a significant subset of target 
genes with Nanog and/or Oct4, it will be interesting to determine if some of these 
common targets that have chromatin modifying functions will be perturbed when the ES 
cells are treated with the collective down-regulation of two or more of the key factors.  
 
Importantly, I identified Jmjd3 which encodes a histone H3K27 demethylase to be a 
downstream target and actively regulated by Esrrb. Jmjd3 has been reported to be 
involved in both cell fate decision and developmental processes (Hong et al., 2007; 
Jepsen et al., 2007; Xiang et al., 2007; Lan et al., 2007; De Santa et al., 2007; Agger et 
al., 2007). It was suggested that Jmjd3 functions through antagonizing the polycomb 
protein-mediated gene silencing (Lan et al., 2007; De Santa et al., 2007; Agger et al., 
2007). However, the function of Jmjd3 in ES cells remains unclear. Matoba et al. showed 
that Jmjd3 was up-regulated after the repression of Oct4 in ES cells (Matoba et al., 2006). 
Thus, it is hypothesized that Jmjd3 could play a positive role in the regulation of 
developmental genes during the processes of lineage commitment. Hence, Jmjd3 could 
potentially regulates the “poised” state of the lineage genes, and in turn contribute to the 
pluripotent properties of the ES cells (Bernstein et al., 2006; Boyer et al., 2006). 
 
Esrrb was previously identified to be a member of the pluripotent interactome which was 
found to be enriched in chromatin modifiers such as histone deacetylase NuRD (p66b and 
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HDAC2), polycomb proteins (YY1, Rnf2 and Rybp), SWI/SNF chromatin remodeling 
(BAF155) complexes and co-repressor Tif1β (Wang et al., 2006). Significantly, Esrrb 
may interact either directly or indirectly with these chromatin modifiers. Some of these 
chromatin modifiers, for example Rnf2 and KAP1 are known to play important role in 
early development and knockout mice die between E6.5-8.5 days (Voncken et al., 2003; 
Cammas et al., 2000). Thus, besides the regulation of chromatin modifiers, Esrrb may 
govern the chromatin state of pluripotent ES cells by its interaction with the chromatin 
modifiers (Wang et al., 2006). 
 
4.5. Regulation of the reprogramming circuitry by Esrrb 
Seminal work by Yamanaka’s group has demonstrated that fully differentiated somatic 
cells can be induced into a pluripotent state by the introduction of only four transcription 
factors, Oct4, Sox2, Klf4 and Myc (Takahashi and Yamanaka, 2006). However, these 
induced pluripotent stem (iPS) cells that were selected based on expression of Fbx15 
could not be considered fully pluripotent because no live chimeric mice were obtained 
from the introduction of the iPS cells into blastocysts.  Improvement of the methods 
using selection based on Oct4 or Nanog expression gave rise to iPS cells that had a global 
transcriptional profile and epigenetic pattern more similar to mouse ES cells. Importantly, 
Nanog iPS cells and Oct4 iPS cells could form viable chimeras and are transmitted 
through the germ line (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007). 
More recently, several groups have shown that pluripotency can be restored when defined 
factors are introduced into somatic cells of human origin (Takahashi et al., 2007; Yu et 
al., 2007; Park et al., 2007). Takahashi et al. (2007) and Park et al. (2007) have 
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demonstrated that application of the same four factors, OCT4, SOX2, KLF4 and MYC, 
can also induce human iPS cells from fetal, neonatal and adult somatic cells. Using a 
slightly different combination of genes, OCT4, SOX2, NANOG and LIN28, Yu et al. 
(2007) are able to reprogram cells originating from human fetal skin and foreskin of a 
newborn to pluripotent iPS cells. The prospect of deriving patient-specific pluripotent 
stem cells from reprogrammed somatic cells has moved the concept of regenerative 
medicine and cell therapy closer to reality. 
 
However, despite these promising results, inherent problems could limit the application 
of these reprogrammed cells in replacement therapy. For example, there is a high 
frequency of tumor formation due to re-activation of retroviral Myc. Nakagawa et al. 
(2007) have recently reproduced the iPS cell derivation by introducing only Oct4, Sox2 
and Klf4. This circumvents the tumorigenicity provoked by Myc re-activation that 
commonly affects chimeric mice generated from the iPS cells. The low efficiency of iPS 
cell generation is another key issue that needs to be resolved. Consequentially, the search 
for alternative factors for inducing reprogramming in somatic cells is an area of great 
interest. As a target of Oct4 and Nanog, Esrrb is positively regulated by these two key 
reprogramming factors. This suggests that endogenous Esrrb may be activated by Oct4 
and Nanog and participates in the process of reprogramming.  
 
The findings of this project uncover the binding of Esrrb within the loci of the known 
reprogramming factors, Oct4, Sox2, Klf2, Klf4, Klf5, Myc, Mycn and Nanog. Notably, the 
bindings, except for Klf2 and Myc, are functional as depletion of Esrrb resulted in the 
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corresponding perturbation of the expression of these reprogramming factor encoding 
genes. Incidentally, Nakagawa et al. (2007) and Blelloch et al. (2007) have recently 
indicated that mycn can substitute for myc in iPS induction. Nakagawa et al. (2007) even 
suggests that myc proteins are dispensable for reprogramming which can be activated by 
Oct4, Sox2 and Klf4.  
 
It is of interest to note that in both studies, a limited array of genes for reprogramming 
functions were screened, and Esrrb was not among the candidates tested (Takahashi et al., 
2006; Yu et al., 2007). Thus the potential of Esrrb as a reprogramming factor is not fully 
explored. Therefore it will be of tremendous interest to validate such roles of Esrrb for 




































Chapter V. Conclusions 
Embryonic stem (ES) cells are remarkable in their ability to propagate indefinitely in 
culture, while retaining the potential to generate every cell type of the organism. 
Understanding the molecular mechanisms that underlie these unique properties will be 
useful for harnessing ES cells for application in regenerative medicine.  The aim of this 
project is to identify transcription factors that are downstream of Nanog and play 
important roles in maintaining the undifferentiated state of ES cells.  
 
This project has confirmed the important role of Nanog in maintaining the self-renewal 
state of the ES cells. shRNA-mediated depletion of Nanog led to the differentiation of ES 
cells which was accompanied by the reduced expression of pluripotent markers and 
elevation of differentiation genes. On the other hand, the Nanog overexpression cell line 
was shown to partially resist the differentiation induced by the addition of RA or 
withdrawal of LIF. This highlights the essential role of Nanog in preventing the 
differentiation of ES cells. Hence, these results are consistent with the findings from 
previous studies that reported the importance of Nanog in ES cells maintenance 
(Chamber et al., 2003; Mitsui et al., 2003; Ivanova et al., 2006).  
 
Using genome-wide affymetrix microarray analysis, 15 genes were identified to be 
putative targets that are positively regulated by Nanog. Esrrb is of special interest for 
several reasons. Firstly, Esrrb is a transcription factor (Pettersson et al., 1996; Xie et al., 
1999; Lu et al., 2001; Sanyal et al., 2002). Secondly, Esrrb has important roles in early 
development and is highly expressed in pluripotent stem cells (Luo et al., 1997; 
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Pettersson et al., 1996). Interestingly, Esrrb was also found to be positively regulated by 
Oct4, another critical regulator of ES cells. Thus, this project has identified Esrrb as a 
direct target of two transcription factors that are critical for ES cell self-renewal.  
 
The novel role of Esrrb in maintaining pluripotent ES cells was uncovered by shRNA-
mediated knockdown. Strikingly, upon Esrrb depletion, ES cells lost their distinctive 
colony morphology and adopted fibroblast phenotype with the loss of alkaline 
phosphatase staining signal. Consistent with this differentiation phenotype, the 
expressions of pluripotent marker genes were down-regulated, while those of lineage 
marker genes were up-regulated, including endoderm, mesoderm, ectoderm and 
trophectoderm. These findings strongly suggest the indispensable role of Esrrb in the 
maintenance of the undifferentiated state of ES cells. Previous studies have reported the 
roles of Esrrb in early embryonic and germ cell development (Luo et al., 1997; 
Mitsunaga et al., 2004). Several other studies have also reported the positive expression 
of Esrrb in pluripotent ES cells (Wei et al., 2005; Palmqvist et al., 2005). However, no 
previous studies have focused on the functions of Esrrb in ES cell biology. Hence, this 
thesis reports the first instance of the critical roles that Esrrb plays in ES cell self-renewal. 
 
To explore the mechanism underlying the function of Esrrb in ES cells, strategies 
involving genome-wide mapping of Esrrb binding and global expression profiling were 
employed. Over eight thousand genes were found to be bound by Esrrb, 64% of which 
showed differential expression upon Esrrb depletion, suggesting a regulatory effect of 
Esrrb on these target genes. It is noteworthy that Esrrb positively regulates many self-
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renewal genes (such as Nanog, Oct4, Sox2, Esrrb, Tbx3 and Tcl1) but represses many 
developmental genes (such as genes from the Hox, Sox, Fox, Pax, Nkx, Pou, Tcf, Myo and  
Tbx families). Hence, one strategy that Esrrb maintains pluripotency is by promoting the 
expression of downstream self-renewal genes while simultaneously repressing the 
activity of lineage specific genes. Furthermore, Esrrb binds to the genes that encode for 
epigenetic modifiers (Jmjd3, Jmjd2b and Jarid1b) and reprogramming factors (Nanog, 
Oct4, Sox2, Klf2, Klf4, Klf5, Myc and Mycn). This suggests a putative role of Esrrb in 
epigenetic processes and the restoration of pluripotency during the reprogramming of 
somatic cells. Moreover, comparison analysis of the genes bound by Esrrb, Nanog and 
Oct4 has identified the overlapped target genes shared by these three transcription factors. 
Interestingly, the function of these common target genes was highly enriched in 
transcriptional regulation. Future efforts should be directed toward the understanding of 
the different mode of regulations on common core targets by each of the three regulators. 
 
Based on these findings, a model was generated to describe the function of Esrrb in 
maintaining the undifferentiated state of ES cells (Figure 5.1). In this model, Esrrb is part 
of the ES cells circuitry network that also consists of other key transcriptional regulators, 
Oct4 and Nanog. Through its regulation of ES cell-associated and developmental genes, 
Esrrb maintains the transcriptional landscape that specifies the self-renewing and 
pluripotent state of ES cells. In addition, by occupying epigenetic regulator encoding 
genes, Esrrb may also be involved in ensuring the epigenetic modifications, conductive 
for the self-renewal of ES cells. 
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In conclusion, this project has made important contributions toward elucidating the 
complexity of cell fate determination and identifying mechanisms for the stable 
propagation of a pluripotent ES cell state. The elucidation of the molecular mechanisms 
governing interactions between the nodes in the transcriptional network have provided 
critical insight into how pluripotency is established and maintained in embryonic stem 
cells. The knowledge gained from my study will thus aid in realizing the therapeutic 
Esrrb
Nanog Oct4 
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Figure 5.1 Model for the role of Esrrb in gene regulation in pluripotent ES cells.  
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Appendix 1. The genes whose expression was reduced in the Nanog-depleted ES cells 
and induced in the Nanog-overexpressed ES cells.  
 
AffyID Gene.Descriptions 
1419577_at RIKEN cDNA A530089I17 gene 
1452341_at enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 
1426555_at serine carboxypeptidase 1 
1428075_at NADH dehydrogenase (ubiquinone) 1 beta subcomplex 4 
1426799_at RAB8B, member RAS oncogene family 
1430985_at RIKEN cDNA 1810027O10 gene 
1418737_at nudix (nucleoside diphosphate linked moiety X)-type motif 2 
1455286_at BTB (POZ) domain containing 1 
1423078_a_at sterol-C4-methyl oxidase-like 
1449254_at secreted phosphoprotein 1 
1448562_at uridine phosphorylase 1 
1449682_s_at RIKEN cDNA 2410129E14 gene 
1433953_at zinc finger protein 277 
1429377_at RIKEN cDNA 2410004A20 gene 
1423911_at protein phosphatase 2, regulatory subunit B (B56), alpha isoform 
1417501_at F-box only protein 6b 
1418649_at EGL nine homolog 3 (C. elegans) 
1434917_at cordon-bleu 
1420619_a_at amino-terminal enhancer of split 
1436926_at estrogen related receptor, beta 
1429278_at Nucleotide binding protein-like 
1421307_at carbonic anhydrase 13 
1426865_a_at neural cell adhesion molecule 1 
1460187_at secreted frizzled-related sequence protein 1 /// RIKEN cDNA 2210415K03 gene 
1448445_at acid phosphatase 6, lysophosphatidic 
1449167_at erythrocyte protein band 4.1-like 4a 
1423702_at H1 histone family, member 0 
1417090_at reticulocalbin 1 
1449590_a_at muscle and microspikes RAS 
1448433_a_at procollagen C-proteinase enhancer protein 
1456242_at LOC433110 














Appendix 2. The genes which are differentially expressed in both Nanog-depleted and 
Esrrb-depleted ES cells.  
 
0610009F02Rik A830025F02Rik BC011209 Creb3 Fut8 
0610039K22Rik A930006D11 BC021614 Crtac1 Fzd5 
0610039N19Rik AA409316 BC050188 Csad Gadd45g 
1110001J03Rik AA517132 BC055811 Csrp1 Gata2 
1110019C08Rik AA517471 BC064011 Ctgf Gata6 
1200009I06Rik AA606869 Bckdha Cyba Gbp2 
1300002F13Rik Aard Bicd2 Cyp2s1 Gdap5 
1300013J15Rik Abcd4 Birc2 Cyr61 Ggt1 
1700007E06Rik Abhd5 Bmp4 D030041H20Rik Gja1 
1700007J06Rik Acacb Bnip2 D030074K08Rik Gjb3 
1700110N18Rik Acas2l Btbd11 D130027M04Rik Gjb5 
1810009M01Rik Acp6 C030003H22Rik D14Ertd725e Gli2 
2010003I19Rik Acta1 C230006B20 D17Ertd288e Gmpr 
2010309L07Rik Actc1 C330005L02Rik D19Ertd678e Gng10 
2010317E24Rik Adfp C530044N13Rik D19Wsu162e Gprasp2 
2010320M18Rik Aes C630016B22Rik D2Bwg1072e Grb10 
2200002D01Rik Agtrap C86987 D8Ertd82e Gsn 
2310006J04Rik AI467606 Cabc1 D9Ertd278e Gyg1 
2310021P13Rik AI850995 Cacnb3 Dag1 H19 
2310031A18Rik AI854628 Calca Dhodh Hand1 
2310066E14Rik AI987986 Cald1 Dhtkd1 Hck 
2310076G13Rik Aire Calm1 Dkk1 Hk1 
2410003B16Rik Ak3l1 Capn5 Dlx3 Hoxa1 
2410004A20Rik Akt1 Car2 Dnaja2 Hrasls3 
2410006F04Rik AL022780 Car3 Dnajc6 Hspa1b 
2410018C20Rik Aldoc Car4 Dp1 Hspa5 
2410039E07Rik Amotl2 Card10 Dtr Hspb2 
2410043F08Rik Ampd3 Ccdc3 Dysf Icam1 
2410076I21Rik Anxa1 Cd24a E2f2 Idb2 
2410146L05Rik Anxa3 Cd97 E2f6 Ifi1 
2600010E01Rik Anxa5 Cdc42ep1 E430026E19Rik Igf2 
2700094F01Rik Apc Cdkn1c Efnb1 Ildr1 
2810489O06Rik Aplp1 Cdkn2b Egln3 Ilk 
3110003A17Rik App Cdyl2 Ehd2 Inhbb 
3110043J09Rik Arhgdib Cebpb Eif4g3 Irx3 
3830417A13Rik Arhgef16 Cebpd Elmo3 Itpka 
4921513H07Rik Arhgef5 Celsr1 Elovl1 Jam2 
4930444M15Rik Arl7 Cfl2 Ercc5 Kcnk1 
4931431C02Rik Armcx2 Chc1l Esrrb Kctd10 
4933426M11Rik Arpc5 Cited2 Esx1 Kdelr3 
4933437F05Rik Atp1a3 Clcn2 Etv4 Kif1c 
5031439A09Rik AU018574 Cldn4 F3 Kit 
5033405K12Rik AU041783 Cldn6 Fabp3 Klf4 
5730453H04Rik AW047273 Cldn7 Fbxo2 Klf5 
5730469M10Rik AW743107 Cln6 Fgf15 Krt1-18 
6030408C04Rik B130017I01Rik Clu Fgf4 Krt1-19 
6030432P03Rik B230104P22Rik Cnn2 Fgfbp1 Krt2-7 
6530411B15Rik B230317C12Rik Cobl Fhl1 Krt2-8 
9330159N05Rik B2m Commd3 FHOS2 Lad1 
9330199F22Rik B430119L13Rik Copeb Flnb Lcn7 
9630008K15Rik B7h3 Cox7a1 Fndc4 Ldh2 
A230098A12Rik Basp1 Cpn1 Fos Lefty1 
A2m Bbx Cpt1a Fstl1 Lgals1 
 
 191
Lgals3 Pgrmc1 Slc27a2 Vim 
Limd1 Phlda1 Slc29a1 Vnn1 
Lin28 Pitx2 Slc40a1 Wbp5 
Liph Pknox2 Slc4a2 Wdr1 
Lmna Pla2g10 Slmap Wnt7b 
LOC224833 Plac1 Smarcd3 Wwtr1 
Loh11cr2a Plk2 Sorbs1 Yaf2 
Lpgat1 Plk3 Sorl1 Zcwcc2 
Lphn2 Plod1 Sparc Zdhhc9 
Lpp Pls3 Spink3 Zfp296 
Lrp2 Pmp22 Spp1 Zwint 




Ly6g6d Ppp1r1a Stard10 
Ly6g6e Ppp2cz Stk17b 
Lzic Prom1 Stmn1 
Manba Prss11 Stoml1 
Mapre1 Prss8 Surf5 
Mat2a Psx1 Tacstd2 
Mbnl3 Psx2 Tagln 
Mfn2 Ptk7 Tax1bp3 
Mitf Rab15 Tcf15 
Mmd Rab3il1 Tcl1 
Mnab Rapgef3 Tdgf1 
Mras Rasgrp2 Tead3 
Mtmr4 Rbms1 Tesk1 
Myh9 Rbp1 Tex27 
Myl7 Rhob Tgm2 
Myo1c Rhou Thbs1 
Myo1f Rnf128 Thy1 
NA Rnf28 Tm4sf2 
Ndrg2 Rpp25 Tm4sf5 
Ngfr Rtkn Tm7sf3 
Nid2 Ryk Tnfsf13 
Nos3 Ryr3 Tnnc1 
Notch2 S100a11 Tnnt1 
Notch4 S100a6 Tp53i5 
Nphs1 Sbsn Tpm1 
Nr0b1 Sec10l1 Tpm2 
Ntn1 Sema4a Tpm4 
Nupr1 Sema4c Trib3 
Oat Sepn1 Trp53inp1 
Otx2 Serpine1 Trps1 
P2y5 Serpine2 Tsrc1 
Pard6b Sestd1 Tst 
Pard6g Sfmbt2 Tubb3 
Parva Sfn Tubb6 
Pcolce Sfrp2 Txnip 
Pde4d Sgce Unc5b 
Pdlim2 Sh3glb1 Usp28 
Pea15 Slc11a1 Utf1 
Peg3 Slc16a3 Vax2 






Appendix 3. ChIP-qPCR validation of the Esrrb ChIP-sequencing library. The column 
“Label” represents the labeling number in figure 3.14. The columns “Locus” and “Peak 
height” respectively represent the Esrrb binding site location and the peak heights 
detected in the Esrrb ChIP-sequencing dataset. Esrrb ChIP-qPCR was used for validation, 
and GFP ChIP-qPCR was as a negative control. Experimental triplicates were performed 
for each Esrrb binding site validation. SD stands for standard deviation.  
 
   









1 chr11:117826126-117826153 7 1.15 0.14 1.07 0.51
2 chr2:31126363-31126373 7 3.77 0.14 1.57 0.22
3 chr7:132459189-132459212 7 2.82 0.14 1.94 0.97
4 chr5:7987752-7987785 7 2.21 0.43 5.51 3.57
5 chr5:77993531-77993608 8 0.99 0.23 3.38 0.27
6 chr5:125382632-125382655 8 0.67 0.11 1.06 0.23
7 chr10:76610868-76610907 8 0.68 0.17 1.19 0.08
8 chr8:123710916-123710972 9 1.95 0.29 1.38 0.13
9 chr2:166166316-166166337 9 3.10 0.46 1.33 0.59
10 chr6:28591071-28591097 9 3.19 0.31 1.29 0.63
11 chr19:28626979-28626987 9 5.17 0.15 0.78 0.18
12 chr19:53083200-53083262 10 2.16 0.32 0.57 0.23
13 chr12:19534802-19534806 10 8.18 0.21 1.47 0.30
14 chr10:88883293-88883349 10 5.33 1.83 1.44 1.07
15 chr8:117896827-117896838 10 7.59 0.70 1.15 0.51
16 chr7:72988913-72988963 10 9.10 0.73 0.91 0.34
17 chr5:138158568-138158586 10 3.11 0.31 0.95 0.10
18 chr19:7330163-7330189 11 1.78 0.30 1.00 0.09
19 chr18:81136253-81136263 11 2.94 0.43 1.42 0.21
20 chr15:81973941-81973951 11 6.20 0.91 0.96 0.28
21 chr9:90068275-90068276 11 3.09 0.45 1.06 0.12
22 chr6:83103356-83103372 11 2.75 0.45 1.02 0.46
23 chr14:28928851-28928868 12 3.58 0.53 0.88 0.33
24 chr13:63309615-63309638 12 3.76 0.37 0.53 0.27
25 chr11:115977657-115977663 12 2.50 0.37 0.44 0.20
26 chr7:127796118-127796169 12 2.92 0.57 1.27 0.96
27 chr2:60176177-60176205 12 6.47 0.32 1.50 0.09
28 chr11:69930756-69930758 15 4.53 0.44 0.49 0.08
29 chr9:55355242-55355271 15 7.87 1.35 0.94 0.43
30 chr7:109420334-109420347 15 3.72 0.75 0.77 0.34
31 chr6:117642305-117642306 15 8.59 0.42 0.55 0.05
32 chr2:169170815-169170822 15 5.09 0.30 1.16 0.35
33 chr11:88837312-88837315 20 25.22 2.19 1.04 0.93
34 chr10:75087576-75087578 20 1.32 0.74 0.81 0.21
35 chr8:123175600-123175601 20 9.99 0.54 1.09 0.56
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36 chr5:126183366-126183376 20 5.59 0.65 0.95 0.13
37 chr3:101570306-101570306 20 10.09 1.49 1.35 0.16
38 chr16:30661422-30661436 25 3.90 0.12 0.65 0.06
39 chr10:33595082-33595083 25 4.18 0.25 1.82 0.89
40 chr5:129597059-129597059 25 4.47 1.27 1.85 0.14
41 chr4:125382110-125382118 25 7.28 0.12 1.59 1.19
42 chr1:136949008-136949013 25 6.61 0.45 1.18 0.34
43 chr18:7627121-7627136 30 4.55 0.28 0.99 0.11
44 chr15:100128398-100128399 30 4.77 0.25 1.11 0.25
45 chr12:103080111-103080115 30 12.22 1.21 0.84 0.13
46 chr10:22396927-22396927 30 2.91 0.18 0.68 0.49
47 chr2:162765063-162765063 30 16.33 1.27 1.20 0.10
48 chr13:65256633-65256634 32 5.07 0.26 0.81 0.24
49 chr7:81702383-81702383 32 5.98 0.33 0.73 0.08
50 chr11:75009646-75009647 33 6.84 0.44 2.73 0.57
51 chr12:105298125-105298125 34 14.94 0.45 0.82 0.04
52 chr5:106116681-106116684 35 6.50 0.68 0.83 0.38
53 chr10:79801820-79801822 36 7.36 0.47 1.30 0.06
54 chr18:80349663-80349664 37 19.13 2.39 0.48 0.06
55 chr10:66491588-66491591 38 13.08 1.75 2.48 0.34
56 chrX:67690979-67690988 39 22.77 2.38 0.99 0.77
57 chr3:88732281-88732284 40 22.29 0.32 1.50 0.45
58 chr9:114650216-114650220 42 9.06 0.42 1.20 0.16
59 chr10:84935339-84935346 43 12.86 0.57 1.04 0.15
60 chr12:102232475-102232484 44 7.16 0.33 1.80 0.48
61 chr5:73130516-73130516 45 6.56 0.84 0.51 0.04
62 chr11:88487368-88487370 46 14.74 1.24 1.16 0.27
63 chr6:118568131-118568135 47 8.02 1.40 0.76 0.09
64 chr13:52234757-52234757 48 23.64 0.31 0.93 0.36
65 chr2:152390344-152390344 49 8.71 0.28 0.84 0.49
66 chr4:117570108-117570112 50 11.83 1.30 1.69 0.50
67 chr5:113570065-113570067 51 9.70 0.81 1.58 0.36
68 chr7:28678589-28678592 52 13.76 2.27 1.46 0.52
69 chr2:179985759-179985759 53 13.02 2.14 0.72 0.42
70 chr12:72055019-72055020 54 17.35 1.21 1.21 0.44
71 chr5:149051358-149051359 55 36.67 1.01 1.19 0.37
72 chr19:61280300-61280300 56 20.29 0.56 1.28 0.63
73 chr1:193419779-193419783 57 12.68 0.46 1.07 0.70
74 chr4:62942115-62942120 58 29.91 0.72 0.89 0.63
75 chr10:77031270-77031270 59 21.31 0.53 0.67 0.09
76 chr2:92225592-92225596 60 37.98 2.87 1.85 0.44
77 chr11:90046146-90046146 61 22.90 1.60 2.07 0.54
78 chr7:101987191-101987193 62 6.77 1.49 0.63 0.07
79 chr2:31293830-31293831 63 19.14 0.43 0.89 0.23
80 chr5:136386836-136386836 64 28.32 0.33 1.02 0.34
81 chr2:167229476-167229477 65 4.86 0.29 1.40 0.14
82 chr7:83779281-83779285 66 41.60 4.75 1.50 0.13
83 chr15:96161593-96161593 67 39.42 0.52 1.14 0.35
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84 chr8:123162021-123162021 68 19.95 0.61 0.83 0.04
85 chr14:23086460-23086468 69 46.13 1.00 1.30 0.11
86 chr10:128140554-128140560 70 16.50 0.50 1.25 0.20
87 chr11:60183027-60183033 71 14.27 5.14 1.08 0.58
88 chr6:54628678-54628678 72 30.82 3.01 1.00 0.22
89 chr5:33853498-33853499 73 17.56 0.56 1.47 0.58
90 chr6:91546030-91546033 74 21.39 0.49 1.37 0.82
91 chr10:59673512-59673514 75 20.90 1.09 1.57 0.66
92 chrX:12618787-12618788 76 56.28 6.75 0.94 0.19
93 chr16:6997220-6997221 77 41.83 0.65 0.57 0.17
94 chr2:164834889-164834892 78 16.85 1.21 0.63 0.31
95 chr12:87391144-87391147 148 133.21 10.29 1.54 0.60
96 chr2:5451939-5451940 245 125.57 3.22 0.96 0.26
97 chr9:20765401-20765401 245 89.59 8.88 1.66 0.31
98 chr8:73576520-73576520 254 317.68 56.71 0.77 0.36
99 chr2:19298400-19298400 259 74.26 7.53 0.89 0.27






































Appendix 4. The genes co-occupied by Esrrb, Oct4 and Nanog  
 
1110012J17Rik Clstn2 Gm443 Nmnat2 Slc27a4 Zfp462 
1700019D03Rik Cnot10 Gm672 Nmur2 Slc35b4 Zfp533 
2610042L04Rik Col18a1 Gnas Nrd1 Slc9a9 Zfp64 
4732435N03Rik Cpxm2 Grinl1a Nrxn1 Smad7 Zic3 
4930555I21Rik Cradd Gsh2 Odz2 Smarcad1 Zmat4 
4931406I20Rik Crtac1 Gtdc1 Odz4 Snai1 
4933426M11Rik Csmd1 Gtf2a1 Osm Sox2 
4933434M16Rik D030011O10Rik Hes1 Otx2 Spnb2 
5033405K12Rik D10Ertd214e Hk2 Oxr1 Spry2 
9430067K14Rik D10Ucla1 Hs6st1 Park2 Spry4 
9630008K15Rik D230005D02Rik Hsd17b3 Pcaf Stard13 
A430065P19Rik D930015E06Rik Ifitm7 Pdcl2 Sulf1 
A930017N06Rik D930036F22Rik Igf2bp1 Pde4d Suz12 
A930041G11Rik Dcbld1 Il6st Pdgfc Syk 
Abca4 Dkk1 Immp2l Phc1 Syt13 
Accn1 Dlgap3 Iqgap1 Pigl Syt9 
Adam19 Dnahc8 Itpr1 Pou5f1 Tbca 
Adcy5 Dok5 Jam2 Ppm1a Tbl1x 
Adrb3 Dpp6 Jarid2 Ppp2r2d Tbx3 
AI790205 Dppa5 Kirrel3 Ppp2r5c Tcf3 
AK037444 Dtnb L3mbtl3 Ptch1 Tcfcp2l1 
Akap12 Dusp4 Lmnb1 Pum1 Tcte2 
Akap2 Ebf1 Loxl1 Qk Tdh 
Akr1b8 Egfl6 Lpp Rage Tead1 
Arhgap8 Egln3 Lrig1 Ralgps2 Tfrc 
Arhgef18 Ehmt1 Lrig3 Ranbp17 Tkt 
Arid5b Elovl6 Lrpprc Rbms3 Tle3 
Atbf1 Enah Lrrn2 Rbpms Tle4 
Atp8a2 Eno1 Ly6c Rest Tmem17 
AY395631 Eomes Lyzl1 Rhpn2 Tnfrsf19 
B130055L09Rik Epha4 Manba Rif1 Tnfsf11 
B3gnt7 Ephb1 Mapkap1 Riok1 Trim24 
BC022623 Esrrb Mbip Ror2 Trp53bp1 
Bmper Etv5 Mif Rutbc2 UBE2H 
Btbd11 Eya1 Msi2h Rybp Ubqln4 
Btbd9 Fbxo36 Mtf2 Sall1 Ubxd3 
C80913 Fgfr1 Myo10 Sdk1 Uck2 
Camk1d Foxn2 Myst2 Sec61g Upp1 
Cbfa2t1h Frmd4b Nanog Sertad2 Upp2 
Cdh5 Ftl1 Ncam1 Sez6 Vti1a 
Cdyl Fyb Ndufs4 Sgk Wdfy3 
Centg2 Fzd5 Negr1 Sipa1l1 Whsc2 
Ches1 Gabbr1 Nfatc2ip Six4 Wwox 
Chst3 Gja1 Nfib Slc16a9 Zbtb24 
Clnk Glis3 Nkx6-1 Slc23a2 Zfp36l1  
 
 
